UA95084C2 - 5-lipoxygenase-activating protein (flap) inhibitors - Google Patents

Info

Publication number

UA95084C2

UA95084C2 UAA200804939A UAA200804939A UA95084C2 UA 95084 C2 UA95084 C2 UA 95084C2 UA A200804939 A UAA200804939 A UA A200804939A UA A200804939 A UAA200804939 A UA A200804939A UA 95084 C2 UA95084 C2 UA 95084C2

Authority

UA

Ukraine

Prior art keywords

substituted

compound

pyridin

formula

unsubstituted

Prior art date

2005-11-04

Links

• Espacenet
• Global Dossier
• Discuss

• 102000004023 5-Lipoxygenase-Activating Proteins Human genes 0.000 title claims abstract 34
• 108090000411 5-Lipoxygenase-Activating Proteins Proteins 0.000 title claims abstract 34
• 239000003112 inhibitor Substances 0.000 title claims 63
• 150000001875 compounds Chemical class 0.000 claims abstract 622
• 150000002617 leukotrienes Chemical class 0.000 claims abstract 230
• 238000000034 method Methods 0.000 claims abstract 189
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract 144
• 201000010099 disease Diseases 0.000 claims abstract 111
• 239000008194 pharmaceutical composition Substances 0.000 claims abstract 95
• 230000001419 dependent effect Effects 0.000 claims abstract 63
• 230000001404 mediated effect Effects 0.000 claims abstract 51
• 230000000694 effects Effects 0.000 claims abstract 40
• 230000000241 respiratory effect Effects 0.000 claims abstract 4
• 230000002526 effect on cardiovascular system Effects 0.000 claims abstract 2
• 239000003814 drug Substances 0.000 claims 128
• 125000000217 alkyl group Chemical group 0.000 claims 115
• 238000011282 treatment Methods 0.000 claims 111
• 241000124008 Mammalia Species 0.000 claims 97
• -1 cinolinyl Chemical group 0.000 claims 97
• 239000000203 mixture Substances 0.000 claims 93
• 208000006673 asthma Diseases 0.000 claims 89
• 125000001072 heteroaryl group Chemical group 0.000 claims 85
• 125000003118 aryl group Chemical group 0.000 claims 74
• 230000015572 biosynthetic process Effects 0.000 claims 66
• 229940079593 drug Drugs 0.000 claims 65
• 108090000623 proteins and genes Proteins 0.000 claims 64
• SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims 60
• 238000006243 chemical reaction Methods 0.000 claims 59
• 238000003786 synthesis reaction Methods 0.000 claims 56
• 239000003795 chemical substances by application Substances 0.000 claims 52
• 125000000753 cycloalkyl group Chemical group 0.000 claims 47
• 102000054766 genetic haplotypes Human genes 0.000 claims 42
• 125000000623 heterocyclic group Chemical group 0.000 claims 42
• 235000002639 sodium chloride Nutrition 0.000 claims 41
• 125000003342 alkenyl group Chemical group 0.000 claims 36
• 150000003839 salts Chemical class 0.000 claims 34
• 208000035475 disorder Diseases 0.000 claims 33
• 230000002265 prevention Effects 0.000 claims 33
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 33
• 208000006011 Stroke Diseases 0.000 claims 32
• 230000002757 inflammatory effect Effects 0.000 claims 31
• 230000037353 metabolic pathway Effects 0.000 claims 30
• 239000000090 biomarker Substances 0.000 claims 28
• 229940002612 prodrug Drugs 0.000 claims 28
• 239000000651 prodrug Substances 0.000 claims 28
• 206010028980 Neoplasm Diseases 0.000 claims 27
• PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 claims 27
• RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 claims 27
• ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims 26
• 239000002253 acid Substances 0.000 claims 25
• 239000005557 antagonist Substances 0.000 claims 25
• 210000001519 tissue Anatomy 0.000 claims 25
• 239000000047 product Substances 0.000 claims 24
• 102000005962 receptors Human genes 0.000 claims 24
• 108020003175 receptors Proteins 0.000 claims 24
• 230000004044 response Effects 0.000 claims 24
• 208000010668 atopic eczema Diseases 0.000 claims 23
• 230000004054 inflammatory process Effects 0.000 claims 23
• 210000000056 organ Anatomy 0.000 claims 23
• 208000024891 symptom Diseases 0.000 claims 23
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims 22
• 206010061218 Inflammation Diseases 0.000 claims 22
• 235000018102 proteins Nutrition 0.000 claims 22
• 102000004169 proteins and genes Human genes 0.000 claims 22
• 208000023504 respiratory system disease Diseases 0.000 claims 22
• 239000000126 substance Substances 0.000 claims 22
• 201000011510 cancer Diseases 0.000 claims 21
• 210000004027 cell Anatomy 0.000 claims 21
• 208000010125 myocardial infarction Diseases 0.000 claims 21
• 125000003831 tetrazolyl group Chemical group 0.000 claims 21
• 230000001225 therapeutic effect Effects 0.000 claims 21
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 20
• WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical class C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims 20
• 229910052799 carbon Inorganic materials 0.000 claims 20
• 108700028369 Alleles Proteins 0.000 claims 19
• 239000002904 solvent Substances 0.000 claims 19
• 125000001424 substituent group Chemical group 0.000 claims 19
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 18
• 229910052736 halogen Inorganic materials 0.000 claims 18
• 150000002367 halogens Chemical class 0.000 claims 18
• 239000000243 solution Substances 0.000 claims 18
• 241000282414 Homo sapiens Species 0.000 claims 17
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 17
• 229940044551 receptor antagonist Drugs 0.000 claims 17
• 239000002464 receptor antagonist Substances 0.000 claims 17
• YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 claims 16
• 125000004404 heteroalkyl group Chemical group 0.000 claims 16
• 239000003199 leukotriene receptor blocking agent Substances 0.000 claims 16
• 239000002773 nucleotide Substances 0.000 claims 16
• 125000003729 nucleotide group Chemical group 0.000 claims 16
• 239000000546 pharmaceutical excipient Substances 0.000 claims 16
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 16
• 238000002560 therapeutic procedure Methods 0.000 claims 16
• 230000000172 allergic effect Effects 0.000 claims 15
• 230000008901 benefit Effects 0.000 claims 15
• 125000004122 cyclic group Chemical group 0.000 claims 15
• 239000011734 sodium Substances 0.000 claims 15
• 206010040070 Septic Shock Diseases 0.000 claims 14
• 230000001154 acute effect Effects 0.000 claims 14
• 239000002585 base Substances 0.000 claims 14
• 210000003979 eosinophil Anatomy 0.000 claims 14
• 210000004072 lung Anatomy 0.000 claims 14
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 14
• 230000004048 modification Effects 0.000 claims 14
• 238000012986 modification Methods 0.000 claims 14
• 238000012544 monitoring process Methods 0.000 claims 14
• 239000012044 organic layer Substances 0.000 claims 14
• 125000006239 protecting group Chemical group 0.000 claims 14
• 208000024535 susceptibility to myocardial infarction Diseases 0.000 claims 14
• 125000002373 5 membered heterocyclic group Chemical group 0.000 claims 13
• 125000004070 6 membered heterocyclic group Chemical group 0.000 claims 13
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 13
• 239000002260 anti-inflammatory agent Substances 0.000 claims 13
• 125000004429 atom Chemical group 0.000 claims 13
• 230000009977 dual effect Effects 0.000 claims 13
• 239000003550 marker Substances 0.000 claims 13
• 230000002062 proliferating effect Effects 0.000 claims 13
• JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 13
• 125000003341 7 membered heterocyclic group Chemical group 0.000 claims 12
• 125000005330 8 membered heterocyclic group Chemical group 0.000 claims 12
• 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 12
• 108010092408 Eosinophil Peroxidase Proteins 0.000 claims 12
• 102000044708 Eosinophil peroxidases Human genes 0.000 claims 12
• YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims 12
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 12
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 12
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims 12
• 230000009471 action Effects 0.000 claims 12
• 229940121363 anti-inflammatory agent Drugs 0.000 claims 12
• 230000004071 biological effect Effects 0.000 claims 12
• 230000008859 change Effects 0.000 claims 12
• 125000003709 fluoroalkyl group Chemical group 0.000 claims 12
• 239000002207 metabolite Substances 0.000 claims 12
• 210000001616 monocyte Anatomy 0.000 claims 12
• 210000000440 neutrophil Anatomy 0.000 claims 12
• 238000012216 screening Methods 0.000 claims 12
• 210000003491 skin Anatomy 0.000 claims 12
• 239000007787 solid Substances 0.000 claims 12
• 239000000725 suspension Substances 0.000 claims 12
• 229940124597 therapeutic agent Drugs 0.000 claims 12
• 206010014824 Endotoxic shock Diseases 0.000 claims 11
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 11
• 125000004432 carbon atom Chemical group C* 0.000 claims 11
• 239000000969 carrier Substances 0.000 claims 11
• 235000019439 ethyl acetate Nutrition 0.000 claims 11
• 230000001965 increasing effect Effects 0.000 claims 11
• 208000015181 infectious disease Diseases 0.000 claims 11
• 229940065725 leukotriene receptor antagonists for obstructive airway diseases Drugs 0.000 claims 11
• 239000007788 liquid Substances 0.000 claims 11
• 230000004060 metabolic process Effects 0.000 claims 11
• 102000054765 polymorphisms of proteins Human genes 0.000 claims 11
• 108090000765 processed proteins & peptides Proteins 0.000 claims 11
• 239000000741 silica gel Substances 0.000 claims 11
• 229910002027 silica gel Inorganic materials 0.000 claims 11
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims 10
• VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims 10
• 208000029523 Interstitial Lung disease Diseases 0.000 claims 10
• 239000004480 active ingredient Substances 0.000 claims 10
• 210000004204 blood vessel Anatomy 0.000 claims 10
• 208000027866 inflammatory disease Diseases 0.000 claims 10
• 230000000704 physical effect Effects 0.000 claims 10
• 208000002815 pulmonary hypertension Diseases 0.000 claims 10
• 238000006722 reduction reaction Methods 0.000 claims 10
• 239000012453 solvate Substances 0.000 claims 10
• 239000003381 stabilizer Substances 0.000 claims 10
• 201000001320 Atherosclerosis Diseases 0.000 claims 9
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 9
• 239000002775 capsule Substances 0.000 claims 9
• 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 9
• 239000003085 diluting agent Substances 0.000 claims 9
• RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 9
• 239000000543 intermediate Substances 0.000 claims 9
• 230000000670 limiting effect Effects 0.000 claims 9
• 229920001184 polypeptide Polymers 0.000 claims 9
• 102000004196 processed proteins & peptides Human genes 0.000 claims 9
• 230000009467 reduction Effects 0.000 claims 9
• 239000007858 starting material Substances 0.000 claims 9
• 238000011269 treatment regimen Methods 0.000 claims 9
• 102000001381 Arachidonate 5-Lipoxygenase Human genes 0.000 claims 8
• 108010093579 Arachidonate 5-lipoxygenase Proteins 0.000 claims 8
• OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims 8
• YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims 8
• 238000010521 absorption reaction Methods 0.000 claims 8
• 239000000556 agonist Substances 0.000 claims 8
• 125000000304 alkynyl group Chemical group 0.000 claims 8
• 150000001413 amino acids Chemical class 0.000 claims 8
• 238000004458 analytical method Methods 0.000 claims 8
• 229940114079 arachidonic acid Drugs 0.000 claims 8
• 235000021342 arachidonic acid Nutrition 0.000 claims 8
• 210000003651 basophil Anatomy 0.000 claims 8
• 230000027455 binding Effects 0.000 claims 8
• 238000002648 combination therapy Methods 0.000 claims 8
• 239000000499 gel Substances 0.000 claims 8
• 238000001802 infusion Methods 0.000 claims 8
• 230000002401 inhibitory effect Effects 0.000 claims 8
• 239000010410 layer Substances 0.000 claims 8
• 238000004519 manufacturing process Methods 0.000 claims 8
• 238000005259 measurement Methods 0.000 claims 8
• 229910052757 nitrogen Inorganic materials 0.000 claims 8
• 238000002360 preparation method Methods 0.000 claims 8
• 239000003755 preservative agent Substances 0.000 claims 8
• 125000004076 pyridyl group Chemical group 0.000 claims 8
• 230000035945 sensitivity Effects 0.000 claims 8
• 238000001356 surgical procedure Methods 0.000 claims 8
• 208000020084 Bone disease Diseases 0.000 claims 7
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims 7
• 230000002159 abnormal effect Effects 0.000 claims 7
• 230000004913 activation Effects 0.000 claims 7
• 230000006978 adaptation Effects 0.000 claims 7
• 239000000443 aerosol Substances 0.000 claims 7
• 208000002205 allergic conjunctivitis Diseases 0.000 claims 7
• 208000026935 allergic disease Diseases 0.000 claims 7
• 239000000872 buffer Substances 0.000 claims 7
• 125000000392 cycloalkenyl group Chemical group 0.000 claims 7
• 125000000524 functional group Chemical group 0.000 claims 7
• 239000000463 material Substances 0.000 claims 7
• 150000007523 nucleic acids Chemical class 0.000 claims 7
• 230000037361 pathway Effects 0.000 claims 7
• 239000000843 powder Substances 0.000 claims 7
• 150000003431 steroids Chemical class 0.000 claims 7
• JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims 7
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 6
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims 6
• UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims 6
• 201000004624 Dermatitis Diseases 0.000 claims 6
• 102000004190 Enzymes Human genes 0.000 claims 6
• 108090000790 Enzymes Proteins 0.000 claims 6
• 206010020751 Hypersensitivity Diseases 0.000 claims 6
• 208000022559 Inflammatory bowel disease Diseases 0.000 claims 6
• AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 6
• 102000003896 Myeloperoxidases Human genes 0.000 claims 6
• 108090000235 Myeloperoxidases Proteins 0.000 claims 6
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims 6
• 235000001014 amino acid Nutrition 0.000 claims 6
• 206010003246 arthritis Diseases 0.000 claims 6
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims 6
• 210000004443 dendritic cell Anatomy 0.000 claims 6
• 239000002552 dosage form Substances 0.000 claims 6
• 230000004064 dysfunction Effects 0.000 claims 6
• 229940088598 enzyme Drugs 0.000 claims 6
• 230000014509 gene expression Effects 0.000 claims 6
• 230000002068 genetic effect Effects 0.000 claims 6
• 210000002216 heart Anatomy 0.000 claims 6
• 125000005842 heteroatom Chemical group 0.000 claims 6
• 210000003630 histaminocyte Anatomy 0.000 claims 6
• 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 6
• 125000001041 indolyl group Chemical group 0.000 claims 6
• 230000005764 inhibitory process Effects 0.000 claims 6
• 238000002347 injection Methods 0.000 claims 6
• 239000007924 injection Substances 0.000 claims 6
• 230000003993 interaction Effects 0.000 claims 6
• 210000002540 macrophage Anatomy 0.000 claims 6
• 208000031225 myocardial ischemia Diseases 0.000 claims 6
• VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims 6
• BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 6
• 230000007115 recruitment Effects 0.000 claims 6
• 230000028327 secretion Effects 0.000 claims 6
• 239000011780 sodium chloride Substances 0.000 claims 6
• 238000012360 testing method Methods 0.000 claims 6
• 125000001544 thienyl group Chemical group 0.000 claims 6
• RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 claims 6
• 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 5
• 208000033309 Analgesic asthma syndrome Diseases 0.000 claims 5
• 206010002329 Aneurysm Diseases 0.000 claims 5
• 206010003557 Asthma exercise induced Diseases 0.000 claims 5
• CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims 5
• 108010074051 C-Reactive Protein Proteins 0.000 claims 5
• 102100032752 C-reactive protein Human genes 0.000 claims 5
• 206010010744 Conjunctivitis allergic Diseases 0.000 claims 5
• 206010011224 Cough Diseases 0.000 claims 5
• 208000004657 Exercise-Induced Asthma Diseases 0.000 claims 5
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 5
• 102000004157 Hydrolases Human genes 0.000 claims 5
• 108090000604 Hydrolases Proteins 0.000 claims 5
• 208000005615 Interstitial Cystitis Diseases 0.000 claims 5
• 241001465754 Metazoa Species 0.000 claims 5
• 102000014962 Monocyte Chemoattractant Proteins Human genes 0.000 claims 5
• 108010064136 Monocyte Chemoattractant Proteins Proteins 0.000 claims 5
• UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 claims 5
• 201000004681 Psoriasis Diseases 0.000 claims 5
• 206010063837 Reperfusion injury Diseases 0.000 claims 5
• 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 5
• YEEZWCHGZNKEEK-UHFFFAOYSA-N Zafirlukast Chemical compound COC1=CC(C(=O)NS(=O)(=O)C=2C(=CC=CC=2)C)=CC=C1CC(C1=C2)=CN(C)C1=CC=C2NC(=O)OC1CCCC1 YEEZWCHGZNKEEK-UHFFFAOYSA-N 0.000 claims 5
• 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 5
• 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 5
• 238000005804 alkylation reaction Methods 0.000 claims 5
• 239000013566 allergen Substances 0.000 claims 5
• 239000003963 antioxidant agent Substances 0.000 claims 5
• 235000006708 antioxidants Nutrition 0.000 claims 5
• 210000004369 blood Anatomy 0.000 claims 5
• 239000008280 blood Substances 0.000 claims 5
• 230000036772 blood pressure Effects 0.000 claims 5
• 210000004556 brain Anatomy 0.000 claims 5
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 5
• 150000001732 carboxylic acid derivatives Chemical class 0.000 claims 5
• 208000023819 chronic asthma Diseases 0.000 claims 5
• 230000001684 chronic effect Effects 0.000 claims 5
• 229940125782 compound 2 Drugs 0.000 claims 5
• 208000006111 contracture Diseases 0.000 claims 5
• 239000003246 corticosteroid Substances 0.000 claims 5
• 239000008298 dragée Substances 0.000 claims 5
• 239000012039 electrophile Substances 0.000 claims 5
• 239000000839 emulsion Substances 0.000 claims 5
• 150000002148 esters Chemical class 0.000 claims 5
• 208000024695 exercise-induced bronchoconstriction Diseases 0.000 claims 5
• 239000000945 filler Substances 0.000 claims 5
• 230000006870 function Effects 0.000 claims 5
• 239000007789 gas Substances 0.000 claims 5
• 230000036541 health Effects 0.000 claims 5
• 208000000122 hyperventilation Diseases 0.000 claims 5
• 230000000870 hyperventilation Effects 0.000 claims 5
• 230000004968 inflammatory condition Effects 0.000 claims 5
• 229910052740 iodine Inorganic materials 0.000 claims 5
• 239000003446 ligand Substances 0.000 claims 5
• 239000002502 liposome Substances 0.000 claims 5
• 229910052751 metal Inorganic materials 0.000 claims 5
• 239000002184 metal Substances 0.000 claims 5
• 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 5
• 229960005127 montelukast Drugs 0.000 claims 5
• 208000024696 nocturnal asthma Diseases 0.000 claims 5
• 108020004707 nucleic acids Proteins 0.000 claims 5
• 102000039446 nucleic acids Human genes 0.000 claims 5
• 208000007892 occupational asthma Diseases 0.000 claims 5
• 239000002245 particle Substances 0.000 claims 5
• 229920000642 polymer Polymers 0.000 claims 5
• NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Substances [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 claims 5
• 229960004583 pranlukast Drugs 0.000 claims 5
• UAJUXJSXCLUTNU-UHFFFAOYSA-N pranlukast Chemical compound C=1C=C(OCCCCC=2C=CC=CC=2)C=CC=1C(=O)NC(C=1)=CC=C(C(C=2)=O)C=1OC=2C=1N=NNN=1 UAJUXJSXCLUTNU-UHFFFAOYSA-N 0.000 claims 5
• XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims 5
• 230000002685 pulmonary effect Effects 0.000 claims 5
• UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 5
• 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 5
• 206010039083 rhinitis Diseases 0.000 claims 5
• 229920006395 saturated elastomer Polymers 0.000 claims 5
• 230000001932 seasonal effect Effects 0.000 claims 5
• 238000000926 separation method Methods 0.000 claims 5
• 238000006467 substitution reaction Methods 0.000 claims 5
• 125000000335 thiazolyl group Chemical group 0.000 claims 5
• 229960004764 zafirlukast Drugs 0.000 claims 5
• 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 4
• RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims 4
• 208000024827 Alzheimer disease Diseases 0.000 claims 4
• 201000006474 Brain Ischemia Diseases 0.000 claims 4
• 206010048962 Brain oedema Diseases 0.000 claims 4
• 206010006458 Bronchitis chronic Diseases 0.000 claims 4
• 208000024172 Cardiovascular disease Diseases 0.000 claims 4
• 206010008120 Cerebral ischaemia Diseases 0.000 claims 4
• PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims 4
• 108010036949 Cyclosporine Proteins 0.000 claims 4
• 201000003883 Cystic fibrosis Diseases 0.000 claims 4
• 108020004414 DNA Proteins 0.000 claims 4
• AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 4
• 206010014561 Emphysema Diseases 0.000 claims 4
• 208000018522 Gastrointestinal disease Diseases 0.000 claims 4
• 108010010803 Gelatin Proteins 0.000 claims 4
• 208000002250 Hematologic Neoplasms Diseases 0.000 claims 4
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 4
• 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 4
• 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 4
• 239000000867 Lipoxygenase Inhibitor Substances 0.000 claims 4
• 208000029725 Metabolic bone disease Diseases 0.000 claims 4
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 4
• 208000019695 Migraine disease Diseases 0.000 claims 4
• 206010062575 Muscle contracture Diseases 0.000 claims 4
• MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 claims 4
• 208000010191 Osteitis Deformans Diseases 0.000 claims 4
• 206010049088 Osteopenia Diseases 0.000 claims 4
• 208000027868 Paget disease Diseases 0.000 claims 4
• 208000018737 Parkinson disease Diseases 0.000 claims 4
• NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims 4
• XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Substances CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims 4
• KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims 4
• SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 claims 4
• RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 claims 4
• 102000054727 Serum Amyloid A Human genes 0.000 claims 4
• 206010040914 Skin reaction Diseases 0.000 claims 4
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 4
• QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims 4
• 206010047115 Vasculitis Diseases 0.000 claims 4
• 206010047163 Vasospasm Diseases 0.000 claims 4
• 150000007513 acids Chemical class 0.000 claims 4
• 239000013543 active substance Substances 0.000 claims 4
• 150000001336 alkenes Chemical class 0.000 claims 4
• 230000007815 allergy Effects 0.000 claims 4
• 125000003277 amino group Chemical group 0.000 claims 4
• 208000007474 aortic aneurysm Diseases 0.000 claims 4
• 208000024744 aspirin-induced respiratory disease Diseases 0.000 claims 4
• 208000024998 atopic conjunctivitis Diseases 0.000 claims 4
• 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims 4
• 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 4
• 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims 4
• 208000006752 brain edema Diseases 0.000 claims 4
• GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 4
• 229910052794 bromium Inorganic materials 0.000 claims 4
• 206010006451 bronchitis Diseases 0.000 claims 4
• 239000011575 calcium Substances 0.000 claims 4
• RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 claims 4
• 208000015114 central nervous system disease Diseases 0.000 claims 4
• 206010008118 cerebral infarction Diseases 0.000 claims 4
• 239000003153 chemical reaction reagent Substances 0.000 claims 4
• 208000007451 chronic bronchitis Diseases 0.000 claims 4
• 229960001265 ciclosporin Drugs 0.000 claims 4
• 208000010877 cognitive disease Diseases 0.000 claims 4
• 229930182912 cyclosporin Natural products 0.000 claims 4
• 230000007423 decrease Effects 0.000 claims 4
• 230000003247 decreasing effect Effects 0.000 claims 4
• 238000012217 deletion Methods 0.000 claims 4
• 230000037430 deletion Effects 0.000 claims 4
• 238000011161 development Methods 0.000 claims 4
• 208000037765 diseases and disorders Diseases 0.000 claims 4
• 238000009826 distribution Methods 0.000 claims 4
• 239000003623 enhancer Substances 0.000 claims 4
• 230000002708 enhancing effect Effects 0.000 claims 4
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 4
• XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 claims 4
• 229960005293 etodolac Drugs 0.000 claims 4
• 125000004612 furopyridinyl group Chemical group O1C(=CC2=C1C=CC=N2)* 0.000 claims 4
• 125000002541 furyl group Chemical group 0.000 claims 4
• 239000008273 gelatin Substances 0.000 claims 4
• 229920000159 gelatin Polymers 0.000 claims 4
• 229940014259 gelatin Drugs 0.000 claims 4
• 235000019322 gelatine Nutrition 0.000 claims 4
• 235000011852 gelatine desserts Nutrition 0.000 claims 4
• 230000012010 growth Effects 0.000 claims 4
• 125000001188 haloalkyl group Chemical group 0.000 claims 4
• 229940088597 hormone Drugs 0.000 claims 4
• 239000005556 hormone Substances 0.000 claims 4
• 125000002883 imidazolyl group Chemical group 0.000 claims 4
• 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims 4
• CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims 4
• 230000003834 intracellular effect Effects 0.000 claims 4
• 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 claims 4
• 125000001786 isothiazolyl group Chemical group 0.000 claims 4
• 125000000842 isoxazolyl group Chemical group 0.000 claims 4
• 210000003734 kidney Anatomy 0.000 claims 4
• 230000003902 lesion Effects 0.000 claims 4
• 210000000265 leukocyte Anatomy 0.000 claims 4
• 230000004807 localization Effects 0.000 claims 4
• 210000004698 lymphocyte Anatomy 0.000 claims 4
• 208000027202 mammary Paget disease Diseases 0.000 claims 4
• 210000003097 mucus Anatomy 0.000 claims 4
• 201000006417 multiple sclerosis Diseases 0.000 claims 4
• 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 claims 4
• 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 4
• 239000003960 organic solvent Substances 0.000 claims 4
• 125000001715 oxadiazolyl group Chemical group 0.000 claims 4
• 125000002971 oxazolyl group Chemical group 0.000 claims 4
• 230000002093 peripheral effect Effects 0.000 claims 4
• 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 claims 4
• 239000006187 pill Substances 0.000 claims 4
• 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 4
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 4
• 239000002243 precursor Substances 0.000 claims 4
• 230000002335 preservative effect Effects 0.000 claims 4
• 230000008569 process Effects 0.000 claims 4
• 238000012545 processing Methods 0.000 claims 4
• 230000001185 psoriatic effect Effects 0.000 claims 4
• 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 claims 4
• 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 claims 4
• 125000003373 pyrazinyl group Chemical group 0.000 claims 4
• 125000003226 pyrazolyl group Chemical group 0.000 claims 4
• 125000002098 pyridazinyl group Chemical group 0.000 claims 4
• 125000000714 pyrimidinyl group Chemical group 0.000 claims 4
• 125000000168 pyrrolyl group Chemical group 0.000 claims 4
• 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims 4
• 210000002345 respiratory system Anatomy 0.000 claims 4
• YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims 4
• 229960002855 simvastatin Drugs 0.000 claims 4
• RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims 4
• 230000035483 skin reaction Effects 0.000 claims 4
• 231100000430 skin reaction Toxicity 0.000 claims 4
• 210000002460 smooth muscle Anatomy 0.000 claims 4
• 235000015424 sodium Nutrition 0.000 claims 4
• 229910052708 sodium Inorganic materials 0.000 claims 4
• 230000009870 specific binding Effects 0.000 claims 4
• 208000020431 spinal cord injury Diseases 0.000 claims 4
• 229910052717 sulfur Inorganic materials 0.000 claims 4
• 239000011593 sulfur Substances 0.000 claims 4
• 239000000829 suppository Substances 0.000 claims 4
• 239000000375 suspending agent Substances 0.000 claims 4
• 238000013268 sustained release Methods 0.000 claims 4
• 239000012730 sustained-release form Substances 0.000 claims 4
• 208000011580 syndromic disease Diseases 0.000 claims 4
• 125000001113 thiadiazolyl group Chemical group 0.000 claims 4
• RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 claims 4
• 231100000331 toxic Toxicity 0.000 claims 4
• 230000002588 toxic effect Effects 0.000 claims 4
• 125000004306 triazinyl group Chemical group 0.000 claims 4
• 125000001425 triazolyl group Chemical group 0.000 claims 4
• 208000019553 vascular disease Diseases 0.000 claims 4
• 229940088594 vitamin Drugs 0.000 claims 4
• 229930003231 vitamin Natural products 0.000 claims 4
• 235000013343 vitamin Nutrition 0.000 claims 4
• 239000011782 vitamin Substances 0.000 claims 4
• MWLSOWXNZPKENC-SSDOTTSWSA-N zileuton Chemical compound C1=CC=C2SC([C@H](N(O)C(N)=O)C)=CC2=C1 MWLSOWXNZPKENC-SSDOTTSWSA-N 0.000 claims 4
• 229960005332 zileuton Drugs 0.000 claims 4
• 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 3
• 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 3
• 229940124125 5 Lipoxygenase inhibitor Drugs 0.000 claims 3
• WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 claims 3
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 3
• BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims 3
• 239000005711 Benzoic acid Substances 0.000 claims 3
• 229940122361 Bisphosphonate Drugs 0.000 claims 3
• 102000004506 Blood Proteins Human genes 0.000 claims 3
• 108010017384 Blood Proteins Proteins 0.000 claims 3
• WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 3
• 206010006487 Bronchostenosis Diseases 0.000 claims 3
• COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 claims 3
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 3
• 229940127291 Calcium channel antagonist Drugs 0.000 claims 3
• 206010010741 Conjunctivitis Diseases 0.000 claims 3
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 3
• 102000004127 Cytokines Human genes 0.000 claims 3
• 108090000695 Cytokines Proteins 0.000 claims 3
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 3
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 3
• 206010012442 Dermatitis contact Diseases 0.000 claims 3
• CYQFCXCEBYINGO-DLBZAZTESA-N Dronabinol Natural products C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@H]21 CYQFCXCEBYINGO-DLBZAZTESA-N 0.000 claims 3
• 206010015943 Eye inflammation Diseases 0.000 claims 3
• 206010019196 Head injury Diseases 0.000 claims 3
• 241000282412 Homo Species 0.000 claims 3
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 3
• OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims 3
• 208000001145 Metabolic Syndrome Diseases 0.000 claims 3
• 241000699670 Mus sp. Species 0.000 claims 3
• 206010030113 Oedema Diseases 0.000 claims 3
• 208000001132 Osteoporosis Diseases 0.000 claims 3
• 229930012538 Paclitaxel Natural products 0.000 claims 3
• 206010061902 Pancreatic neoplasm Diseases 0.000 claims 3
• ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims 3
• 229920003171 Poly (ethylene oxide) Polymers 0.000 claims 3
• KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims 3
• RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 3
• 241001303601 Rosacea Species 0.000 claims 3
• 241000159610 Roya <green alga> Species 0.000 claims 3
• 229920002125 Sokalan® Polymers 0.000 claims 3
• 229920002472 Starch Polymers 0.000 claims 3
• CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 claims 3
• 208000024780 Urticaria Diseases 0.000 claims 3
• 208000027418 Wounds and injury Diseases 0.000 claims 3
• 235000011054 acetic acid Nutrition 0.000 claims 3
• DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 3
• 229960001138 acetylsalicylic acid Drugs 0.000 claims 3
• 239000002671 adjuvant Substances 0.000 claims 3
• 208000037883 airway inflammation Diseases 0.000 claims 3
• 150000001345 alkine derivatives Chemical group 0.000 claims 3
• 201000010105 allergic rhinitis Diseases 0.000 claims 3
• 150000001408 amides Chemical class 0.000 claims 3
• 150000001412 amines Chemical group 0.000 claims 3
• 230000003110 anti-inflammatory effect Effects 0.000 claims 3
• 238000013459 approach Methods 0.000 claims 3
• 239000007864 aqueous solution Substances 0.000 claims 3
• 239000007900 aqueous suspension Substances 0.000 claims 3
• 125000006615 aromatic heterocyclic group Chemical group 0.000 claims 3
• 235000010323 ascorbic acid Nutrition 0.000 claims 3
• 239000011668 ascorbic acid Substances 0.000 claims 3
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 3
• 229960002170 azathioprine Drugs 0.000 claims 3
• LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 claims 3
• 235000010233 benzoic acid Nutrition 0.000 claims 3
• 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims 3
• 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims 3
• 230000017531 blood circulation Effects 0.000 claims 3
• 210000000988 bone and bone Anatomy 0.000 claims 3
• 230000010072 bone remodeling Effects 0.000 claims 3
• 230000007883 bronchodilation Effects 0.000 claims 3
• 229910052791 calcium Inorganic materials 0.000 claims 3
• 239000000480 calcium channel blocker Substances 0.000 claims 3
• 239000001768 carboxy methyl cellulose Substances 0.000 claims 3
• 230000000747 cardiac effect Effects 0.000 claims 3
• 229960000590 celecoxib Drugs 0.000 claims 3
• 210000000170 cell membrane Anatomy 0.000 claims 3
• 239000000460 chlorine Substances 0.000 claims 3
• 208000037976 chronic inflammation Diseases 0.000 claims 3
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 3
• 238000011284 combination treatment Methods 0.000 claims 3
• 208000010247 contact dermatitis Diseases 0.000 claims 3
• 229960001334 corticosteroids Drugs 0.000 claims 3
• 239000013058 crude material Substances 0.000 claims 3
• 239000013078 crystal Substances 0.000 claims 3
• 229960004397 cyclophosphamide Drugs 0.000 claims 3
• 230000002354 daily effect Effects 0.000 claims 3
• CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 claims 3
• 238000002405 diagnostic procedure Methods 0.000 claims 3
• 235000014113 dietary fatty acids Nutrition 0.000 claims 3
• 239000002270 dispersing agent Substances 0.000 claims 3
• 229960004242 dronabinol Drugs 0.000 claims 3
• 239000003937 drug carrier Substances 0.000 claims 3
• 230000008406 drug-drug interaction Effects 0.000 claims 3
• 210000002889 endothelial cell Anatomy 0.000 claims 3
• 238000013265 extended release Methods 0.000 claims 3
• 208000030533 eye disease Diseases 0.000 claims 3
• 239000000194 fatty acid Substances 0.000 claims 3
• 229930195729 fatty acid Natural products 0.000 claims 3
• 238000009472 formulation Methods 0.000 claims 3
• 230000037433 frameshift Effects 0.000 claims 3
• 235000011167 hydrochloric acid Nutrition 0.000 claims 3
• 229910052739 hydrogen Inorganic materials 0.000 claims 3
• 230000000642 iatrogenic effect Effects 0.000 claims 3
• 150000002466 imines Chemical class 0.000 claims 3
• 230000001976 improved effect Effects 0.000 claims 3
• 150000002475 indoles Chemical class 0.000 claims 3
• 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 claims 3
• 208000014674 injury Diseases 0.000 claims 3
• 238000003780 insertion Methods 0.000 claims 3
• 230000037431 insertion Effects 0.000 claims 3
• 230000003434 inspiratory effect Effects 0.000 claims 3
• 238000001990 intravenous administration Methods 0.000 claims 3
• 150000002500 ions Chemical class 0.000 claims 3
• 208000028867 ischemia Diseases 0.000 claims 3
• 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims 3
• 239000008101 lactose Substances 0.000 claims 3
• 150000002632 lipids Chemical class 0.000 claims 3
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 3
• 229940126601 medicinal product Drugs 0.000 claims 3
• 238000002844 melting Methods 0.000 claims 3
• 206010027599 migraine Diseases 0.000 claims 3
• 238000002156 mixing Methods 0.000 claims 3
• 210000004877 mucosa Anatomy 0.000 claims 3
• 208000004296 neuralgia Diseases 0.000 claims 3
• 230000002981 neuropathic effect Effects 0.000 claims 3
• 208000021722 neuropathic pain Diseases 0.000 claims 3
• 231100000252 nontoxic Toxicity 0.000 claims 3
• 230000003000 nontoxic effect Effects 0.000 claims 3
• 239000012038 nucleophile Substances 0.000 claims 3
• 230000035764 nutrition Effects 0.000 claims 3
• 235000016709 nutrition Nutrition 0.000 claims 3
• 201000008482 osteoarthritis Diseases 0.000 claims 3
• 229910052760 oxygen Inorganic materials 0.000 claims 3
• 239000001301 oxygen Substances 0.000 claims 3
• 229960001592 paclitaxel Drugs 0.000 claims 3
• 201000002528 pancreatic cancer Diseases 0.000 claims 3
• 208000008443 pancreatic carcinoma Diseases 0.000 claims 3
• 229940043138 pentosan polysulfate Drugs 0.000 claims 3
• 235000011007 phosphoric acid Nutrition 0.000 claims 3
• 239000001267 polyvinylpyrrolidone Substances 0.000 claims 3
• 231100000683 possible toxicity Toxicity 0.000 claims 3
• 229960004618 prednisone Drugs 0.000 claims 3
• 230000000069 prophylactic effect Effects 0.000 claims 3
• HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 claims 3
• 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims 3
• 230000002829 reductive effect Effects 0.000 claims 3
• 239000011347 resin Substances 0.000 claims 3
• 229920005989 resin Polymers 0.000 claims 3
• 201000004193 respiratory failure Diseases 0.000 claims 3
• 208000032253 retinal ischemia Diseases 0.000 claims 3
• 206010039073 rheumatoid arthritis Diseases 0.000 claims 3
• 229960000371 rofecoxib Drugs 0.000 claims 3
• RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 claims 3
• 201000004700 rosacea Diseases 0.000 claims 3
• 230000036303 septic shock Effects 0.000 claims 3
• 159000000000 sodium salts Chemical class 0.000 claims 3
• 239000000600 sorbitol Substances 0.000 claims 3
• 210000000278 spinal cord Anatomy 0.000 claims 3
• 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims 3
• 238000010189 synthetic method Methods 0.000 claims 3
• RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 3
• 230000037317 transdermal delivery Effects 0.000 claims 3
• 238000013519 translation Methods 0.000 claims 3
• 230000032258 transport Effects 0.000 claims 3
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims 3
• 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 3
• LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 claims 3
• 230000002792 vascular Effects 0.000 claims 3
• 230000008728 vascular permeability Effects 0.000 claims 3
• 239000005526 vasoconstrictor agent Substances 0.000 claims 3
• 235000015112 vegetable and seed oil Nutrition 0.000 claims 3
• 239000008158 vegetable oil Substances 0.000 claims 3
• 238000009423 ventilation Methods 0.000 claims 3
• ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 claims 2
• FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 claims 2
• 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims 2
• ZCZVGQCBSJLDDS-UHFFFAOYSA-N 1,2,3,4-tetrahydro-1,8-naphthyridine Chemical class C1=CC=C2CCCNC2=N1 ZCZVGQCBSJLDDS-UHFFFAOYSA-N 0.000 claims 2
• LBUJPTNKIBCYBY-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoline Chemical compound C1=CC=C2CCCNC2=C1 LBUJPTNKIBCYBY-UHFFFAOYSA-N 0.000 claims 2
• HJTAZXHBEBIQQX-UHFFFAOYSA-N 1,5-bis(chloromethyl)naphthalene Chemical compound C1=CC=C2C(CCl)=CC=CC2=C1CCl HJTAZXHBEBIQQX-UHFFFAOYSA-N 0.000 claims 2
• IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims 2
• DGHHQBMTXTWTJV-BQAIUKQQSA-N 119413-54-6 Chemical compound Cl.C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 DGHHQBMTXTWTJV-BQAIUKQQSA-N 0.000 claims 2
• XWKFPIODWVPXLX-UHFFFAOYSA-N 2,5-dimethylpyridine Chemical compound CC1=CC=C(C)N=C1 XWKFPIODWVPXLX-UHFFFAOYSA-N 0.000 claims 2
• HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims 2
• BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 claims 2
• XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 claims 2
• WNWVKZTYMQWFHE-UHFFFAOYSA-N 4-ethylmorpholine Chemical compound [CH2]CN1CCOCC1 WNWVKZTYMQWFHE-UHFFFAOYSA-N 0.000 claims 2
• WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 claims 2
• STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims 2
• ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims 2
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 2
• NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims 2
• 208000004476 Acute Coronary Syndrome Diseases 0.000 claims 2
• 208000009304 Acute Kidney Injury Diseases 0.000 claims 2
• 229930024421 Adenine Natural products 0.000 claims 2
• GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 claims 2
• NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 claims 2
• 239000004475 Arginine Substances 0.000 claims 2
• 102000015790 Asparaginase Human genes 0.000 claims 2
• 108010024976 Asparaginase Proteins 0.000 claims 2
• 206010003645 Atopy Diseases 0.000 claims 2
• 239000004342 Benzoyl peroxide Substances 0.000 claims 2
• OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 claims 2
• 239000002083 C09CA01 - Losartan Substances 0.000 claims 2
• 101100310222 Caenorhabditis briggsae she-1 gene Proteins 0.000 claims 2
• 241000283707 Capra Species 0.000 claims 2
• CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims 2
• 102000004171 Cathepsin K Human genes 0.000 claims 2
• 108090000625 Cathepsin K Proteins 0.000 claims 2
• ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 2
• HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims 2
• 108010061846 Cholesterol Ester Transfer Proteins Proteins 0.000 claims 2
• 102000012336 Cholesterol Ester Transfer Proteins Human genes 0.000 claims 2
• 208000017667 Chronic Disease Diseases 0.000 claims 2
• KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims 2
• ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims 2
• RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 claims 2
• 229920002307 Dextran Polymers 0.000 claims 2
• 108010061435 Enalapril Proteins 0.000 claims 2
• 241000792859 Enema Species 0.000 claims 2
• KMTRUDSVKNLOMY-UHFFFAOYSA-N Ethylene carbonate Chemical class O=C1OCCO1 KMTRUDSVKNLOMY-UHFFFAOYSA-N 0.000 claims 2
• 206010016207 Familial Mediterranean fever Diseases 0.000 claims 2
• 206010016654 Fibrosis Diseases 0.000 claims 2
• 238000006641 Fischer synthesis reaction Methods 0.000 claims 2
• PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 2
• GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 2
• VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims 2
• 208000007882 Gastritis Diseases 0.000 claims 2
• 206010018364 Glomerulonephritis Diseases 0.000 claims 2
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 2
• 235000010469 Glycine max Nutrition 0.000 claims 2
• 108010001483 Glycogen Synthase Proteins 0.000 claims 2
• AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims 2
• 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 2
• 241000202943 Hernandia sonora Species 0.000 claims 2
• XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 claims 2
• XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 claims 2
• 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 2
• 102000006992 Interferon-alpha Human genes 0.000 claims 2
• 108010047761 Interferon-alpha Proteins 0.000 claims 2
• 102000014150 Interferons Human genes 0.000 claims 2
• 108010050904 Interferons Proteins 0.000 claims 2
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 2
• 239000005517 L01XE01 - Imatinib Substances 0.000 claims 2
• 239000002841 Lewis acid Substances 0.000 claims 2
• ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 claims 2
• FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 claims 2
• 102100031545 Microsomal triglyceride transfer protein large subunit Human genes 0.000 claims 2
• PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 claims 2
• YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 2
• 238000005481 NMR spectroscopy Methods 0.000 claims 2
• BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 claims 2
• CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims 2
• GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 claims 2
• 108020004485 Nonsense Codon Proteins 0.000 claims 2
• 102000004316 Oxidoreductases Human genes 0.000 claims 2
• 108090000854 Oxidoreductases Proteins 0.000 claims 2
• 102000003982 Parathyroid hormone Human genes 0.000 claims 2
• 108090000445 Parathyroid hormone Proteins 0.000 claims 2
• 208000030831 Peripheral arterial occlusive disease Diseases 0.000 claims 2
• GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims 2
• NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 2
• 206010035664 Pneumonia Diseases 0.000 claims 2
• 239000004698 Polyethylene Substances 0.000 claims 2
• 239000002202 Polyethylene glycol Substances 0.000 claims 2
• WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims 2
• TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 claims 2
• 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 claims 2
• 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 claims 2
• 206010037597 Pyelonephritis acute Diseases 0.000 claims 2
• 206010037660 Pyrexia Diseases 0.000 claims 2
• LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 claims 2
• 208000033626 Renal failure acute Diseases 0.000 claims 2
• 208000004756 Respiratory Insufficiency Diseases 0.000 claims 2
• 206010039085 Rhinitis allergic Diseases 0.000 claims 2
• YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 claims 2
• 108700028909 Serum Amyloid A Proteins 0.000 claims 2
• 101710190759 Serum amyloid A protein Proteins 0.000 claims 2
• 229910020163 SiOCl Inorganic materials 0.000 claims 2
• CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims 2
• 241000282887 Suidae Species 0.000 claims 2
• RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 claims 2
• QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims 2
• BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 claims 2
• FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims 2
• YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims 2
• GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims 2
• DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims 2
• 229930003268 Vitamin C Natural products 0.000 claims 2
• 206010047700 Vomiting Diseases 0.000 claims 2
• 238000009825 accumulation Methods 0.000 claims 2
• 201000011040 acute kidney failure Diseases 0.000 claims 2
• 201000001555 acute pyelonephritis Diseases 0.000 claims 2
• 229960000643 adenine Drugs 0.000 claims 2
• 239000000853 adhesive Substances 0.000 claims 2
• 230000001070 adhesive effect Effects 0.000 claims 2
• 230000002411 adverse Effects 0.000 claims 2
• 229960000548 alemtuzumab Drugs 0.000 claims 2
• 125000003545 alkoxy group Chemical group 0.000 claims 2
• SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims 2
• OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 claims 2
• 229960003459 allopurinol Drugs 0.000 claims 2
• 229910000147 aluminium phosphate Inorganic materials 0.000 claims 2
• VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 claims 2
• 150000003863 ammonium salts Chemical class 0.000 claims 2
• 239000003263 anabolic agent Substances 0.000 claims 2
• 229940070021 anabolic steroids Drugs 0.000 claims 2
• 239000002333 angiotensin II receptor antagonist Substances 0.000 claims 2
• 238000010171 animal model Methods 0.000 claims 2
• 230000008485 antagonism Effects 0.000 claims 2
• 230000002280 anti-androgenic effect Effects 0.000 claims 2
• 229940046836 anti-estrogen Drugs 0.000 claims 2
• 230000001833 anti-estrogenic effect Effects 0.000 claims 2
• 229940124599 anti-inflammatory drug Drugs 0.000 claims 2
• 239000000051 antiandrogen Substances 0.000 claims 2
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 2
• GOLCXWYRSKYTSP-UHFFFAOYSA-N arsenic trioxide Inorganic materials O1[As]2O[As]1O2 GOLCXWYRSKYTSP-UHFFFAOYSA-N 0.000 claims 2
• 229960002594 arsenic trioxide Drugs 0.000 claims 2
• 229960005070 ascorbic acid Drugs 0.000 claims 2
• 229960003272 asparaginase Drugs 0.000 claims 2
• DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 claims 2
• 125000002393 azetidinyl group Chemical group 0.000 claims 2
• 229940064856 azulfidine Drugs 0.000 claims 2
• 230000004888 barrier function Effects 0.000 claims 2
• 230000009286 beneficial effect Effects 0.000 claims 2
• 235000019400 benzoyl peroxide Nutrition 0.000 claims 2
• 239000002876 beta blocker Substances 0.000 claims 2
• 229940097320 beta blocking agent Drugs 0.000 claims 2
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 2
• 229960000397 bevacizumab Drugs 0.000 claims 2
• 230000031018 biological processes and functions Effects 0.000 claims 2
• 150000004663 bisphosphonates Chemical class 0.000 claims 2
• 230000000903 blocking effect Effects 0.000 claims 2
• UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 claims 2
• 239000012267 brine Substances 0.000 claims 2
• SXDBWCPKPHAZSM-UHFFFAOYSA-N bromic acid Chemical compound OBr(=O)=O SXDBWCPKPHAZSM-UHFFFAOYSA-N 0.000 claims 2
• 229960002092 busulfan Drugs 0.000 claims 2
• 125000002837 carbocyclic group Chemical group 0.000 claims 2
• 239000011203 carbon fibre reinforced carbon Substances 0.000 claims 2
• 230000003197 catalytic effect Effects 0.000 claims 2
• 238000006555 catalytic reaction Methods 0.000 claims 2
• 238000004113 cell culture Methods 0.000 claims 2
• 210000003169 central nervous system Anatomy 0.000 claims 2
• 229960005395 cetuximab Drugs 0.000 claims 2
• 125000003636 chemical group Chemical group 0.000 claims 2
• HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
• 208000023652 chronic gastritis Diseases 0.000 claims 2
• 230000006020 chronic inflammation Effects 0.000 claims 2
• 208000020832 chronic kidney disease Diseases 0.000 claims 2
• 208000022831 chronic renal failure syndrome Diseases 0.000 claims 2
• DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 2
• 229960004316 cisplatin Drugs 0.000 claims 2
• 235000015165 citric acid Nutrition 0.000 claims 2
• 238000011260 co-administration Methods 0.000 claims 2
• 238000000576 coating method Methods 0.000 claims 2
• 229940110456 cocoa butter Drugs 0.000 claims 2
• 235000019868 cocoa butter Nutrition 0.000 claims 2
• 238000007796 conventional method Methods 0.000 claims 2
• 239000006071 cream Substances 0.000 claims 2
• 238000002425 crystallisation Methods 0.000 claims 2
• 230000008025 crystallization Effects 0.000 claims 2
• 125000004093 cyano group Chemical group *C#N 0.000 claims 2
• RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 claims 2
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 2
• 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 claims 2
• 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
• 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 2
• 201000003146 cystitis Diseases 0.000 claims 2
• GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims 2
• 230000006378 damage Effects 0.000 claims 2
• STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims 2
• 229960000975 daunorubicin Drugs 0.000 claims 2
• 230000007812 deficiency Effects 0.000 claims 2
• 229940027008 deltasone Drugs 0.000 claims 2
• 238000001514 detection method Methods 0.000 claims 2
• 229960002086 dextran Drugs 0.000 claims 2
• DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims 2
• 229960001259 diclofenac Drugs 0.000 claims 2
• 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 claims 2
• 229960001760 dimethyl sulfoxide Drugs 0.000 claims 2
• OSVXSBDYLRYLIG-UHFFFAOYSA-N dioxidochlorine(.) Chemical compound O=Cl=O OSVXSBDYLRYLIG-UHFFFAOYSA-N 0.000 claims 2
• 238000004090 dissolution Methods 0.000 claims 2
• 239000003534 dna topoisomerase inhibitor Substances 0.000 claims 2
• 229960004679 doxorubicin Drugs 0.000 claims 2
• 239000000975 dye Substances 0.000 claims 2
• 229940121647 egfr inhibitor Drugs 0.000 claims 2
• 239000003995 emulsifying agent Substances 0.000 claims 2
• GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 claims 2
• 229960000873 enalapril Drugs 0.000 claims 2
• 239000007920 enema Substances 0.000 claims 2
• 229940079360 enema for constipation Drugs 0.000 claims 2
• 239000003248 enzyme activator Substances 0.000 claims 2
• 201000001564 eosinophilic gastroenteritis Diseases 0.000 claims 2
• 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 2
• 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 2
• 230000003628 erosive effect Effects 0.000 claims 2
• 239000000328 estrogen antagonist Substances 0.000 claims 2
• CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 claims 2
• YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 claims 2
• 229960002297 fenofibrate Drugs 0.000 claims 2
• 230000004761 fibrosis Effects 0.000 claims 2
• 239000000706 filtrate Substances 0.000 claims 2
• 239000012530 fluid Substances 0.000 claims 2
• 239000011737 fluorine Substances 0.000 claims 2
• 229910052731 fluorine Inorganic materials 0.000 claims 2
• 229960002949 fluorouracil Drugs 0.000 claims 2
• 229960003765 fluvastatin Drugs 0.000 claims 2
• OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims 2
• 239000012458 free base Substances 0.000 claims 2
• 238000002290 gas chromatography-mass spectrometry Methods 0.000 claims 2
• 230000030135 gastric motility Effects 0.000 claims 2
• 230000005176 gastrointestinal motility Effects 0.000 claims 2
• 229960000578 gemtuzumab Drugs 0.000 claims 2
• 238000003205 genotyping method Methods 0.000 claims 2
• 239000011521 glass Substances 0.000 claims 2
• 125000005456 glyceride group Chemical group 0.000 claims 2
• 235000011187 glycerol Nutrition 0.000 claims 2
• XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical class C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 claims 2
• MFWNKCLOYSRHCJ-BTTYYORXSA-N granisetron Chemical compound C1=CC=C2C(C(=O)N[C@H]3C[C@H]4CCC[C@@H](C3)N4C)=NN(C)C2=C1 MFWNKCLOYSRHCJ-BTTYYORXSA-N 0.000 claims 2
• 229960003727 granisetron Drugs 0.000 claims 2
• 239000008187 granular material Substances 0.000 claims 2
• 125000005843 halogen group Chemical group 0.000 claims 2
• 201000011200 hepatorenal syndrome Diseases 0.000 claims 2
• 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 claims 2
• 150000004677 hydrates Chemical class 0.000 claims 2
• 239000001257 hydrogen Substances 0.000 claims 2
• XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims 2
• 238000007327 hydrogenolysis reaction Methods 0.000 claims 2
• 238000006460 hydrolysis reaction Methods 0.000 claims 2
• 230000002209 hydrophobic effect Effects 0.000 claims 2
• 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 2
• 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 2
• 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 2
• 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 2
• UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 2
• 206010020718 hyperplasia Diseases 0.000 claims 2
• 230000009610 hypersensitivity Effects 0.000 claims 2
• WQYVRQLZKVEZGA-UHFFFAOYSA-N hypochlorite Chemical compound Cl[O-] WQYVRQLZKVEZGA-UHFFFAOYSA-N 0.000 claims 2
• 229960000908 idarubicin Drugs 0.000 claims 2
• KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims 2
• 229960002411 imatinib Drugs 0.000 claims 2
• 229960000905 indomethacin Drugs 0.000 claims 2
• 239000004615 ingredient Substances 0.000 claims 2
• 150000007529 inorganic bases Chemical class 0.000 claims 2
• 229910052500 inorganic mineral Inorganic materials 0.000 claims 2
• 229940047124 interferons Drugs 0.000 claims 2
• 208000036971 interstitial lung disease 2 Diseases 0.000 claims 2
• 238000010253 intravenous injection Methods 0.000 claims 2
• 239000011630 iodine Substances 0.000 claims 2
• 230000000302 ischemic effect Effects 0.000 claims 2
• SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 claims 2
• 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 2
• FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 claims 2
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
• 150000002576 ketones Chemical class 0.000 claims 2
• DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 claims 2
• 229960000991 ketoprofen Drugs 0.000 claims 2
• 208000017169 kidney disease Diseases 0.000 claims 2
• JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims 2
• 235000014655 lactic acid Nutrition 0.000 claims 2
• 150000007517 lewis acids Chemical class 0.000 claims 2
• 238000004895 liquid chromatography mass spectrometry Methods 0.000 claims 2
• 230000033001 locomotion Effects 0.000 claims 2
• 229960004773 losartan Drugs 0.000 claims 2
• KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 claims 2
• 229960004844 lovastatin Drugs 0.000 claims 2
• PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 claims 2
• QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 claims 2
• 210000003563 lymphoid tissue Anatomy 0.000 claims 2
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 2
• 238000012423 maintenance Methods 0.000 claims 2
• HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 claims 2
• 229960004961 mechlorethamine Drugs 0.000 claims 2
• HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 claims 2
• SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 claims 2
• 229960001924 melphalan Drugs 0.000 claims 2
• 230000008018 melting Effects 0.000 claims 2
• 239000012528 membrane Substances 0.000 claims 2
• 210000004379 membrane Anatomy 0.000 claims 2
• QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 claims 2
• 229910052753 mercury Inorganic materials 0.000 claims 2
• KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 claims 2
• 208000030159 metabolic disease Diseases 0.000 claims 2
• 230000002503 metabolic effect Effects 0.000 claims 2
• VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 claims 2
• 229940098779 methanesulfonic acid Drugs 0.000 claims 2
• 229960000485 methotrexate Drugs 0.000 claims 2
• 108010038232 microsomal triglyceride transfer protein Proteins 0.000 claims 2
• 235000010755 mineral Nutrition 0.000 claims 2
• 239000011707 mineral Substances 0.000 claims 2
• 229940112801 mobic Drugs 0.000 claims 2
• 229950007856 mofetil Drugs 0.000 claims 2
• 125000002950 monocyclic group Chemical group 0.000 claims 2
• TXXHDPDFNKHHGW-UHFFFAOYSA-N muconic acid Chemical compound OC(=O)C=CC=CC(O)=O TXXHDPDFNKHHGW-UHFFFAOYSA-N 0.000 claims 2
• 210000004400 mucous membrane Anatomy 0.000 claims 2
• YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 2
• 229960004270 nabumetone Drugs 0.000 claims 2
• 239000002105 nanoparticle Substances 0.000 claims 2
• 229960002009 naproxen Drugs 0.000 claims 2
• CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims 2
• 230000003589 nefrotoxic effect Effects 0.000 claims 2
• 231100000381 nephrotoxic Toxicity 0.000 claims 2
• 229910017604 nitric acid Inorganic materials 0.000 claims 2
• 239000002736 nonionic surfactant Substances 0.000 claims 2
• 210000000633 nuclear envelope Anatomy 0.000 claims 2
• 230000000414 obstructive effect Effects 0.000 claims 2
• 229960000470 omalizumab Drugs 0.000 claims 2
• 229960005343 ondansetron Drugs 0.000 claims 2
• 150000007524 organic acids Chemical class 0.000 claims 2
• 150000007530 organic bases Chemical class 0.000 claims 2
• 239000003791 organic solvent mixture Substances 0.000 claims 2
• 230000003204 osmotic effect Effects 0.000 claims 2
• CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 claims 2
• SXCHDDWMFBETRA-UHFFFAOYSA-N oxazinan-3-one Chemical class O=C1CCCON1 SXCHDDWMFBETRA-UHFFFAOYSA-N 0.000 claims 2
• 230000003647 oxidation Effects 0.000 claims 2
• 238000007254 oxidation reaction Methods 0.000 claims 2
• 150000002924 oxiranes Chemical class 0.000 claims 2
• RZXMPPFPUUCRFN-UHFFFAOYSA-N p-toluidine Chemical compound CC1=CC=C(N)C=C1 RZXMPPFPUUCRFN-UHFFFAOYSA-N 0.000 claims 2
• FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims 2
• 201000005675 papillary conjunctivitis Diseases 0.000 claims 2
• 229960001319 parathyroid hormone Drugs 0.000 claims 2
• 239000000199 parathyroid hormone Substances 0.000 claims 2
• 230000036961 partial effect Effects 0.000 claims 2
• 230000035515 penetration Effects 0.000 claims 2
• 239000000825 pharmaceutical preparation Substances 0.000 claims 2
• HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 claims 2
• XUWHAWMETYGRKB-UHFFFAOYSA-N piperidin-2-one Chemical class O=C1CCCCN1 XUWHAWMETYGRKB-UHFFFAOYSA-N 0.000 claims 2
• 229960002702 piroxicam Drugs 0.000 claims 2
• QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 claims 2
• 229960002797 pitavastatin Drugs 0.000 claims 2
• RHGYHLPFVJEAOC-FFNUKLMVSA-L pitavastatin calcium Chemical compound [Ca+2].[O-]C(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1.[O-]C(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 RHGYHLPFVJEAOC-FFNUKLMVSA-L 0.000 claims 2
• 229920003023 plastic Polymers 0.000 claims 2
• 239000004033 plastic Substances 0.000 claims 2
• 229910052697 platinum Inorganic materials 0.000 claims 2
• 125000003367 polycyclic group Chemical group 0.000 claims 2
• 229920001223 polyethylene glycol Polymers 0.000 claims 2
• 229960002965 pravastatin Drugs 0.000 claims 2
• TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 claims 2
• 239000002244 precipitate Substances 0.000 claims 2
• 230000001737 promoting effect Effects 0.000 claims 2
• 229940080818 propionamide Drugs 0.000 claims 2
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
• 208000005069 pulmonary fibrosis Diseases 0.000 claims 2
• AOJFQRQNPXYVLM-UHFFFAOYSA-N pyridin-1-ium;chloride Chemical compound [Cl-].C1=CC=[NH+]C=C1 AOJFQRQNPXYVLM-UHFFFAOYSA-N 0.000 claims 2
• LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims 2
• SMUQFGGVLNAIOZ-UHFFFAOYSA-N quinaldine Chemical compound C1=CC=CC2=NC(C)=CC=C21 SMUQFGGVLNAIOZ-UHFFFAOYSA-N 0.000 claims 2
• LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 claims 2
• 229930185107 quinolinone Natural products 0.000 claims 2
• 125000005493 quinolyl group Chemical group 0.000 claims 2
• ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims 2
• 239000000376 reactant Substances 0.000 claims 2
• 238000001953 recrystallisation Methods 0.000 claims 2
• 238000010992 reflux Methods 0.000 claims 2
• 238000007634 remodeling Methods 0.000 claims 2
• 230000010410 reperfusion Effects 0.000 claims 2
• 230000029058 respiratory gaseous exchange Effects 0.000 claims 2
• 125000006413 ring segment Chemical group 0.000 claims 2
• 229960000672 rosuvastatin Drugs 0.000 claims 2
• BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 claims 2
• 235000002020 sage Nutrition 0.000 claims 2
• 229960004889 salicylic acid Drugs 0.000 claims 2
• 230000037390 scarring Effects 0.000 claims 2
• 230000011664 signaling Effects 0.000 claims 2
• QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims 2
• 229960002930 sirolimus Drugs 0.000 claims 2
• 235000010413 sodium alginate Nutrition 0.000 claims 2
• 239000000661 sodium alginate Substances 0.000 claims 2
• 229940005550 sodium alginate Drugs 0.000 claims 2
• 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims 2
• 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims 2
• 235000011121 sodium hydroxide Nutrition 0.000 claims 2
• AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 claims 2
• 235000019345 sodium thiosulphate Nutrition 0.000 claims 2
• HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 claims 2
• 239000008247 solid mixture Substances 0.000 claims 2
• 229940087854 solu-medrol Drugs 0.000 claims 2
• 239000004059 squalene synthase inhibitor Substances 0.000 claims 2
• 235000019698 starch Nutrition 0.000 claims 2
• 230000000638 stimulation Effects 0.000 claims 2
• 125000000547 substituted alkyl group Chemical group 0.000 claims 2
• 235000000346 sugar Nutrition 0.000 claims 2
• NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 claims 2
• 230000002195 synergetic effect Effects 0.000 claims 2
• 239000003826 tablet Substances 0.000 claims 2
• 229960001967 tacrolimus Drugs 0.000 claims 2
• QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 claims 2
• 239000000454 talc Substances 0.000 claims 2
• 229910052623 talc Inorganic materials 0.000 claims 2
• 235000012222 talc Nutrition 0.000 claims 2
• 229960004964 temozolomide Drugs 0.000 claims 2
• DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 claims 2
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
• XBXCNNQPRYLIDE-UHFFFAOYSA-N tert-butylcarbamic acid Chemical group CC(C)(C)NC(O)=O XBXCNNQPRYLIDE-UHFFFAOYSA-N 0.000 claims 2
• RAOIDOHSFRTOEL-UHFFFAOYSA-N tetrahydrothiophene Chemical class C1CCSC1 RAOIDOHSFRTOEL-UHFFFAOYSA-N 0.000 claims 2
• 150000001467 thiazolidinediones Chemical class 0.000 claims 2
• 239000002562 thickening agent Substances 0.000 claims 2
• 125000003396 thiol group Chemical class [H]S* 0.000 claims 2
• 150000003573 thiols Chemical class 0.000 claims 2
• FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 claims 2
• 229940113082 thymine Drugs 0.000 claims 2
• 229960003087 tioguanine Drugs 0.000 claims 2
• MNRILEROXIRVNJ-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=NC=N[C]21 MNRILEROXIRVNJ-UHFFFAOYSA-N 0.000 claims 2
• 239000010936 titanium Substances 0.000 claims 2
• 238000011200 topical administration Methods 0.000 claims 2
• 229940044693 topoisomerase inhibitor Drugs 0.000 claims 2
• 229960000303 topotecan Drugs 0.000 claims 2
• 239000003440 toxic substance Substances 0.000 claims 2
• 231100000419 toxicity Toxicity 0.000 claims 2
• 230000001988 toxicity Effects 0.000 claims 2
• 239000003053 toxin Substances 0.000 claims 2
• 231100000765 toxin Toxicity 0.000 claims 2
• 108700012359 toxins Proteins 0.000 claims 2
• 210000003437 trachea Anatomy 0.000 claims 2
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 2
• 238000012546 transfer Methods 0.000 claims 2
• 230000000472 traumatic effect Effects 0.000 claims 2
• 229960001727 tretinoin Drugs 0.000 claims 2
• XFNJVJPLKCPIBV-UHFFFAOYSA-N trimethylenediamine Chemical compound NCCCN XFNJVJPLKCPIBV-UHFFFAOYSA-N 0.000 claims 2
• 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims 2
• 239000005483 tyrosine kinase inhibitor Substances 0.000 claims 2
• 125000004417 unsaturated alkyl group Chemical group 0.000 claims 2
• 229960002004 valdecoxib Drugs 0.000 claims 2
• 230000025033 vasoconstriction Effects 0.000 claims 2
• 230000024883 vasodilation Effects 0.000 claims 2
• 208000018464 vernal keratoconjunctivitis Diseases 0.000 claims 2
• 235000019154 vitamin C Nutrition 0.000 claims 2
• 239000011718 vitamin C Substances 0.000 claims 2
• 230000029663 wound healing Effects 0.000 claims 2
• QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 claims 1
• HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 claims 1
• 125000006727 (C1-C6) alkenyl group Chemical group 0.000 claims 1
• WSWCOQWTEOXDQX-MQQKCMAXSA-M (E,E)-sorbate Chemical compound C\C=C\C=C\C([O-])=O WSWCOQWTEOXDQX-MQQKCMAXSA-M 0.000 claims 1
• METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 claims 1
• BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims 1
• TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 claims 1
• WOGITNXCNOTRLK-VOTSOKGWSA-N (e)-3-phenylprop-2-enoyl chloride Chemical compound ClC(=O)\C=C\C1=CC=CC=C1 WOGITNXCNOTRLK-VOTSOKGWSA-N 0.000 claims 1
• WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 claims 1
• JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 claims 1
• DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 claims 1
• OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 claims 1
• KVGZZAHHUNAVKZ-UHFFFAOYSA-N 1,4-Dioxin Chemical compound O1C=COC=C1 KVGZZAHHUNAVKZ-UHFFFAOYSA-N 0.000 claims 1
• QEMSVZNTSXPFJA-HNAYVOBHSA-N 1-[(1s,2s)-1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl]-4-phenylpiperidin-4-ol Chemical compound C1([C@H](O)[C@H](C)N2CCC(O)(CC2)C=2C=CC=CC=2)=CC=C(O)C=C1 QEMSVZNTSXPFJA-HNAYVOBHSA-N 0.000 claims 1
• ZABMHLDQFJHDSC-UHFFFAOYSA-N 2,3-dihydro-1,3-oxazole Chemical compound C1NC=CO1 ZABMHLDQFJHDSC-UHFFFAOYSA-N 0.000 claims 1
• LWTIGYSPAXKMDG-UHFFFAOYSA-N 2,3-dihydro-1h-imidazole Chemical compound C1NC=CN1 LWTIGYSPAXKMDG-UHFFFAOYSA-N 0.000 claims 1
• ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 claims 1
• SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 claims 1
• JECYNCQXXKQDJN-UHFFFAOYSA-N 2-(2-methylhexan-2-yloxymethyl)oxirane Chemical compound CCCCC(C)(C)OCC1CO1 JECYNCQXXKQDJN-UHFFFAOYSA-N 0.000 claims 1
• JPMRGPPMXHGKRO-UHFFFAOYSA-N 2-(chloromethyl)pyridine hydrochloride Chemical compound Cl.ClCC1=CC=CC=N1 JPMRGPPMXHGKRO-UHFFFAOYSA-N 0.000 claims 1
• HNLXNOZHXNSSPN-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CC(C)(C)CC(C)(C)C1=CC=C(OCCOCCOCCOCCOCCOCCOCCO)C=C1 HNLXNOZHXNSSPN-UHFFFAOYSA-N 0.000 claims 1
• RXNZFHIEDZEUQM-UHFFFAOYSA-N 2-bromo-1,3-thiazole Chemical compound BrC1=NC=CS1 RXNZFHIEDZEUQM-UHFFFAOYSA-N 0.000 claims 1
• REXUYBKPWIPONM-UHFFFAOYSA-N 2-bromoacetonitrile Chemical compound BrCC#N REXUYBKPWIPONM-UHFFFAOYSA-N 0.000 claims 1
• UYXQLQUXXCIFQM-UHFFFAOYSA-N 2-hydroxy-1,3,2$l^{5}-dioxaphospholane 2-oxide Chemical compound OP1(=O)OCCO1 UYXQLQUXXCIFQM-UHFFFAOYSA-N 0.000 claims 1
• SGUAFYQXFOLMHL-UHFFFAOYSA-N 2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide Chemical compound C=1C=C(O)C(C(N)=O)=CC=1C(O)CNC(C)CCC1=CC=CC=C1 SGUAFYQXFOLMHL-UHFFFAOYSA-N 0.000 claims 1
• UPHOPMSGKZNELG-UHFFFAOYSA-N 2-hydroxynaphthalene-1-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)=C(O)C=CC2=C1 UPHOPMSGKZNELG-UHFFFAOYSA-N 0.000 claims 1
• HDECRAPHCDXMIJ-UHFFFAOYSA-N 2-methylbenzenesulfonyl chloride Chemical compound CC1=CC=CC=C1S(Cl)(=O)=O HDECRAPHCDXMIJ-UHFFFAOYSA-N 0.000 claims 1
• VSWICNJIUPRZIK-UHFFFAOYSA-N 2-piperideine Chemical compound C1CNC=CC1 VSWICNJIUPRZIK-UHFFFAOYSA-N 0.000 claims 1
• 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims 1
• 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
• RSEBUVRVKCANEP-UHFFFAOYSA-N 2-pyrroline Chemical compound C1CC=CN1 RSEBUVRVKCANEP-UHFFFAOYSA-N 0.000 claims 1
• MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 claims 1
• MLMQPDHYNJCQAO-UHFFFAOYSA-N 3,3-dimethylbutyric acid Chemical compound CC(C)(C)CC(O)=O MLMQPDHYNJCQAO-UHFFFAOYSA-N 0.000 claims 1
• XLZYKTYMLBOINK-UHFFFAOYSA-N 3-(4-hydroxybenzoyl)benzoic acid Chemical compound OC(=O)C1=CC=CC(C(=O)C=2C=CC(O)=CC=2)=C1 XLZYKTYMLBOINK-UHFFFAOYSA-N 0.000 claims 1
• NZOONKHCNQFYCI-UHFFFAOYSA-N 3-[3-tert-butylsulfanyl-1-[(4-chlorophenyl)methyl]-5-(quinolin-2-ylmethoxy)indol-2-yl]-2,2-dimethylpropanoic acid Chemical compound C12=CC=C(OCC=3N=C4C=CC=CC4=CC=3)C=C2C(SC(C)(C)C)=C(CC(C)(C)C(O)=O)N1CC1=CC=C(Cl)C=C1 NZOONKHCNQFYCI-UHFFFAOYSA-N 0.000 claims 1
• WSNKEJIFARPOSQ-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-(1-benzothiophen-2-ylmethyl)benzamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C(=O)NCC2=CC3=C(S2)C=CC=C3)C=CC=1 WSNKEJIFARPOSQ-UHFFFAOYSA-N 0.000 claims 1
• VTNULXUEOJMRKZ-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-(2H-tetrazol-5-ylmethyl)benzamide Chemical compound N=1NN=NC=1CNC(C1=CC(=CC=C1)OC1=NC(=CC(=C1)CN)C(F)(F)F)=O VTNULXUEOJMRKZ-UHFFFAOYSA-N 0.000 claims 1
• GDSLUYKCPYECNN-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-[(4-fluorophenyl)methyl]benzamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C(=O)NCC2=CC=C(C=C2)F)C=CC=1 GDSLUYKCPYECNN-UHFFFAOYSA-N 0.000 claims 1
• ZMCQQCBOZIGNRV-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-[2-(1,2,4-triazol-1-yl)ethyl]benzamide Chemical compound NCC1=CC(OC2=CC=CC(=C2)C(=O)NCCN2C=NC=N2)=NC(=C1)C(F)(F)F ZMCQQCBOZIGNRV-UHFFFAOYSA-N 0.000 claims 1
• AJZDHLHTTJRNQJ-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-[2-(tetrazol-1-yl)ethyl]benzamide Chemical compound N1(N=NN=C1)CCNC(C1=CC(=CC=C1)OC1=NC(=CC(=C1)CN)C(F)(F)F)=O AJZDHLHTTJRNQJ-UHFFFAOYSA-N 0.000 claims 1
• MZSAMHOCTRNOIZ-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-phenylaniline Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(NC2=CC=CC=C2)C=CC=1 MZSAMHOCTRNOIZ-UHFFFAOYSA-N 0.000 claims 1
• HAEQAUJYNHQVHV-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-phenylbenzamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C(=O)NC2=CC=CC=C2)C=CC=1 HAEQAUJYNHQVHV-UHFFFAOYSA-N 0.000 claims 1
• OQEBBZSWEGYTPG-UHFFFAOYSA-N 3-aminobutanoic acid Chemical compound CC(N)CC(O)=O OQEBBZSWEGYTPG-UHFFFAOYSA-N 0.000 claims 1
• OBFSQMXGZIYMMN-UHFFFAOYSA-N 3-chloro-2-hexadecylpyridine Chemical compound CCCCCCCCCCCCCCCCC1=NC=CC=C1Cl OBFSQMXGZIYMMN-UHFFFAOYSA-N 0.000 claims 1
• NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 claims 1
• ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 claims 1
• NXTDJHZGHOFSQG-UHFFFAOYSA-N 3-phenoxybenzoic acid Chemical compound OC(=O)C1=CC=CC(OC=2C=CC=CC=2)=C1 NXTDJHZGHOFSQG-UHFFFAOYSA-N 0.000 claims 1
• 125000001963 4 membered heterocyclic group Chemical group 0.000 claims 1
• AZASWMGVGQEVCS-UHFFFAOYSA-N 4,4-dimethylpentan-2-one Chemical compound CC(=O)CC(C)(C)C AZASWMGVGQEVCS-UHFFFAOYSA-N 0.000 claims 1
• FUEVYCNUMABXOJ-UHFFFAOYSA-N 4-(3-methylphenyl)oxan-4-ol Chemical compound CC1=CC=CC(C2(O)CCOCC2)=C1 FUEVYCNUMABXOJ-UHFFFAOYSA-N 0.000 claims 1
• CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 claims 1
• QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims 1
• RDEYORKJEDLLDB-DQVHGTJVSA-N 5-Hydroperoxyeicosatetraenoic acid Chemical compound CCCCCCCCCCC\C=C\C=C\C(\OO)=C\C=C\C(O)=O RDEYORKJEDLLDB-DQVHGTJVSA-N 0.000 claims 1
• 101150053132 ABCI1 gene Proteins 0.000 claims 1
• 239000005541 ACE inhibitor Substances 0.000 claims 1
• 244000215068 Acacia senegal Species 0.000 claims 1
• OQLZINXFSUDMHM-UHFFFAOYSA-N Acetamidine Chemical compound CC(N)=N OQLZINXFSUDMHM-UHFFFAOYSA-N 0.000 claims 1
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
• 241000251468 Actinopterygii Species 0.000 claims 1
• 229920001817 Agar Polymers 0.000 claims 1
• 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 claims 1
• 206010002198 Anaphylactic reaction Diseases 0.000 claims 1
• 206010002383 Angina Pectoris Diseases 0.000 claims 1
• 206010059245 Angiopathy Diseases 0.000 claims 1
• 229940123413 Angiotensin II antagonist Drugs 0.000 claims 1
• 102000012739 Anion Transport Proteins Human genes 0.000 claims 1
• 108010079442 Anion Transport Proteins Proteins 0.000 claims 1
• 241001547866 Anoda Species 0.000 claims 1
• 102100029470 Apolipoprotein E Human genes 0.000 claims 1
• 101710095339 Apolipoprotein E Proteins 0.000 claims 1
• 200000000007 Arterial disease Diseases 0.000 claims 1
• 208000009657 Aspirin-Induced Asthma Diseases 0.000 claims 1
• 241000271566 Aves Species 0.000 claims 1
• BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims 1
• 240000005220 Bischofia javanica Species 0.000 claims 1
• 235000010893 Bischofia javanica Nutrition 0.000 claims 1
• BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 claims 1
• 241000283725 Bos Species 0.000 claims 1
• 241000283690 Bos taurus Species 0.000 claims 1
• 241000566113 Branta sandvicensis Species 0.000 claims 1
• 101710117545 C protein Proteins 0.000 claims 1
• 239000002080 C09CA02 - Eprosartan Substances 0.000 claims 1
• 239000004072 C09CA03 - Valsartan Substances 0.000 claims 1
• 239000002947 C09CA04 - Irbesartan Substances 0.000 claims 1
• 239000002053 C09CA06 - Candesartan Substances 0.000 claims 1
• 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 1
• 101100291844 Caenorhabditis elegans moc-5 gene Proteins 0.000 claims 1
• 241000282472 Canis lupus familiaris Species 0.000 claims 1
• WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims 1
• 229920002134 Carboxymethyl cellulose Polymers 0.000 claims 1
• 108010078791 Carrier Proteins Proteins 0.000 claims 1
• 241000700198 Cavia Species 0.000 claims 1
• PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 claims 1
• 241000282693 Cercopithecidae Species 0.000 claims 1
• LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 claims 1
• 241000507614 Chama Species 0.000 claims 1
• 108091006146 Channels Proteins 0.000 claims 1
• 239000004155 Chlorine dioxide Substances 0.000 claims 1
• RENMDAKOXSCIGH-UHFFFAOYSA-N Chloroacetonitrile Chemical compound ClCC#N RENMDAKOXSCIGH-UHFFFAOYSA-N 0.000 claims 1
• VGCXGMAHQTYDJK-UHFFFAOYSA-N Chloroacetyl chloride Chemical compound ClCC(Cl)=O VGCXGMAHQTYDJK-UHFFFAOYSA-N 0.000 claims 1
• 241000511343 Chondrostoma nasus Species 0.000 claims 1
• 206010009126 Chronic respiratory failure Diseases 0.000 claims 1
• WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 claims 1
• 108091026890 Coding region Proteins 0.000 claims 1
• 102000008186 Collagen Human genes 0.000 claims 1
• 108010035532 Collagen Proteins 0.000 claims 1
• 241001327708 Coriaria sarmentosa Species 0.000 claims 1
• 229920002261 Corn starch Polymers 0.000 claims 1
• 208000011231 Crohn disease Diseases 0.000 claims 1
• 229920002785 Croscarmellose sodium Polymers 0.000 claims 1
• 229920000858 Cyclodextrin Polymers 0.000 claims 1
• HTJDQJBWANPRPF-UHFFFAOYSA-N Cyclopropylamine Chemical compound NC1CC1 HTJDQJBWANPRPF-UHFFFAOYSA-N 0.000 claims 1
• OJLOPKGSLYJEMD-LNQMSSPSSA-N Cyotec Chemical compound CCCCC(C)(O)CC=C[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC OJLOPKGSLYJEMD-LNQMSSPSSA-N 0.000 claims 1
• 102000002137 Cysteinyl leukotriene receptor 1 Human genes 0.000 claims 1
• 108050009460 Cysteinyl leukotriene receptor 1 Proteins 0.000 claims 1
• 102000004155 Cysteinyl leukotriene receptor 2 Human genes 0.000 claims 1
• 108090000655 Cysteinyl leukotriene receptor 2 Proteins 0.000 claims 1
• 102000018832 Cytochromes Human genes 0.000 claims 1
• 108010052832 Cytochromes Proteins 0.000 claims 1
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
• RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 claims 1
• VVNCNSJFMMFHPL-VKHMYHEASA-N D-penicillamine Chemical group CC(C)(S)[C@@H](N)C(O)=O VVNCNSJFMMFHPL-VKHMYHEASA-N 0.000 claims 1
• 206010012239 Delusion Diseases 0.000 claims 1
• 206010012438 Dermatitis atopic Diseases 0.000 claims 1
• 206010012441 Dermatitis bullous Diseases 0.000 claims 1
• FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims 1
• 239000004338 Dichlorodifluoromethane Substances 0.000 claims 1
• XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 claims 1
• 102000004860 Dipeptidases Human genes 0.000 claims 1
• 108090001081 Dipeptidases Proteins 0.000 claims 1
• 101100460157 Drosophila melanogaster nenya gene Proteins 0.000 claims 1
• 102100034428 Dual specificity protein phosphatase 1 Human genes 0.000 claims 1
• 101710132784 Dual specificity protein phosphatase 1 Proteins 0.000 claims 1
• LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 claims 1
• 102000002045 Endothelin Human genes 0.000 claims 1
• 108050009340 Endothelin Proteins 0.000 claims 1
• 241000283086 Equidae Species 0.000 claims 1
• OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 claims 1
• 235000014066 European mistletoe Nutrition 0.000 claims 1
• 206010015866 Extravasation Diseases 0.000 claims 1
• 241000282326 Felis catus Species 0.000 claims 1
• 108010029961 Filgrastim Proteins 0.000 claims 1
• 244000182067 Fraxinus ornus Species 0.000 claims 1
• 235000002917 Fraxinus ornus Nutrition 0.000 claims 1
• 229940123457 Free radical scavenger Drugs 0.000 claims 1
• 108091007911 GSKs Proteins 0.000 claims 1
• 241001547860 Gaya Species 0.000 claims 1
• 241000206672 Gelidium Species 0.000 claims 1
• 108700039691 Genetic Promoter Regions Proteins 0.000 claims 1
• 208000007465 Giant cell arteritis Diseases 0.000 claims 1
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 1
• 244000068988 Glycine max Species 0.000 claims 1
• 102000004103 Glycogen Synthase Kinases Human genes 0.000 claims 1
• 108090000288 Glycoproteins Proteins 0.000 claims 1
• 102000003886 Glycoproteins Human genes 0.000 claims 1
• 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 claims 1
• 229920000084 Gum arabic Polymers 0.000 claims 1
• 239000012981 Hank's balanced salt solution Substances 0.000 claims 1
• 206010019280 Heart failures Diseases 0.000 claims 1
• HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims 1
• 229920001499 Heparinoid Polymers 0.000 claims 1
• 241000282418 Hominidae Species 0.000 claims 1
• 101000578774 Homo sapiens MAP kinase-activated protein kinase 5 Proteins 0.000 claims 1
• 101001018259 Homo sapiens Microtubule-associated serine/threonine-protein kinase 1 Proteins 0.000 claims 1
• 101000741790 Homo sapiens Peroxisome proliferator-activated receptor gamma Proteins 0.000 claims 1
• 101000693728 Homo sapiens S-acyl fatty acid synthase thioesterase, medium chain Proteins 0.000 claims 1
• 101000788251 Homo sapiens Trace amine-associated receptor 6 Proteins 0.000 claims 1
• 206010020772 Hypertension Diseases 0.000 claims 1
• 206010021143 Hypoxia Diseases 0.000 claims 1
• 102000004388 Interleukin-4 Human genes 0.000 claims 1
• 108090000978 Interleukin-4 Proteins 0.000 claims 1
• 102000004889 Interleukin-6 Human genes 0.000 claims 1
• 108090001005 Interleukin-6 Proteins 0.000 claims 1
• 206010061246 Intervertebral disc degeneration Diseases 0.000 claims 1
• 241000907506 Israel turkey meningoencephalomyelitis virus Species 0.000 claims 1
• 241001091433 Itea Species 0.000 claims 1
• 208000011200 Kawasaki disease Diseases 0.000 claims 1
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 1
• FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 1
• 102000007330 LDL Lipoproteins Human genes 0.000 claims 1
• 108010007622 LDL Lipoproteins Proteins 0.000 claims 1
• 102000000853 LDL receptors Human genes 0.000 claims 1
• 108010001831 LDL receptors Proteins 0.000 claims 1
• 239000012448 Lithium borohydride Substances 0.000 claims 1
• 102100030817 Liver carboxylesterase 1 Human genes 0.000 claims 1
• 101710181187 Liver carboxylesterase 1 Proteins 0.000 claims 1
• 208000019693 Lung disease Diseases 0.000 claims 1
• 206010025323 Lymphomas Diseases 0.000 claims 1
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
• 239000004472 Lysine Substances 0.000 claims 1
• 102000043136 MAP kinase family Human genes 0.000 claims 1
• 108091054455 MAP kinase family Proteins 0.000 claims 1
• 102100028396 MAP kinase-activated protein kinase 5 Human genes 0.000 claims 1
• FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims 1
• 241001446467 Mama Species 0.000 claims 1
• 229930195725 Mannitol Natural products 0.000 claims 1
• 244000062730 Melissa officinalis Species 0.000 claims 1
• 235000010654 Melissa officinalis Nutrition 0.000 claims 1
• UEZVMMHDMIWARA-UHFFFAOYSA-N Metaphosphoric acid Chemical compound OP(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-N 0.000 claims 1
• 239000012359 Methanesulfonyl chloride Substances 0.000 claims 1
• 229920000168 Microcrystalline cellulose Polymers 0.000 claims 1
• TXXHDPDFNKHHGW-CCAGOZQPSA-N Muconic acid Natural products OC(=O)\C=C/C=C\C(O)=O TXXHDPDFNKHHGW-CCAGOZQPSA-N 0.000 claims 1
• 101100498160 Mus musculus Dach1 gene Proteins 0.000 claims 1
• 101500025412 Mus musculus Processed cyclic AMP-responsive element-binding protein 3-like protein 1 Proteins 0.000 claims 1
• 101100310622 Mus musculus Soga1 gene Proteins 0.000 claims 1
• 235000009421 Myristica fragrans Nutrition 0.000 claims 1
• OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims 1
• WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 1
• 102100031869 N-alpha-acetyltransferase 35, NatC auxiliary subunit Human genes 0.000 claims 1
• AFBPFSWMIHJQDM-UHFFFAOYSA-N N-methyl-N-phenylamine Natural products CNC1=CC=CC=C1 AFBPFSWMIHJQDM-UHFFFAOYSA-N 0.000 claims 1
• CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 claims 1
• MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical class CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 claims 1
• 101150027985 NAA35 gene Proteins 0.000 claims 1
• 208000012902 Nervous system disease Diseases 0.000 claims 1
• PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims 1
• 102000008299 Nitric Oxide Synthase Human genes 0.000 claims 1
• 108010021487 Nitric Oxide Synthase Proteins 0.000 claims 1
• 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
• 241000283965 Ochotona princeps Species 0.000 claims 1
• 206010030111 Oedema mucosal Diseases 0.000 claims 1
• 241000207836 Olea <angiosperm> Species 0.000 claims 1
• 241000283973 Oryctolagus cuniculus Species 0.000 claims 1
• CWKFWBJJNNPGAM-IPZCTEOASA-N Ozagrel hydrochloride Chemical compound Cl.C1=CC(/C=C/C(=O)O)=CC=C1CN1C=NC=C1 CWKFWBJJNNPGAM-IPZCTEOASA-N 0.000 claims 1
• 229910019142 PO4 Inorganic materials 0.000 claims 1
• 208000002193 Pain Diseases 0.000 claims 1
• 241000282579 Pan Species 0.000 claims 1
• 241001659863 Panna Species 0.000 claims 1
• 241001192924 Parna Species 0.000 claims 1
• 208000037273 Pathologic Processes Diseases 0.000 claims 1
• 241001494479 Pecora Species 0.000 claims 1
• YNPNZTXNASCQKK-UHFFFAOYSA-N Phenanthrene Natural products C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 claims 1
• 108010064785 Phospholipases Proteins 0.000 claims 1
• 102000015439 Phospholipases Human genes 0.000 claims 1
• OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 1
• 206010036030 Polyarthritis Diseases 0.000 claims 1
• 229920000148 Polycarbophil calcium Polymers 0.000 claims 1
• 229920001213 Polysorbate 20 Polymers 0.000 claims 1
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 1
• 241000288906 Primates Species 0.000 claims 1
• 102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 claims 1
• 108050003243 Prostaglandin G/H synthase 1 Proteins 0.000 claims 1
• 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 claims 1
• 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 claims 1
• IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 claims 1
• 241000700159 Rattus Species 0.000 claims 1
• 108020004511 Recombinant DNA Proteins 0.000 claims 1
• 206010063897 Renal ischaemia Diseases 0.000 claims 1
• 206010038910 Retinitis Diseases 0.000 claims 1
• 206010039094 Rhinitis perennial Diseases 0.000 claims 1
• 208000036284 Rhinitis seasonal Diseases 0.000 claims 1
• 244000152640 Rhipsalis cassutha Species 0.000 claims 1
• 235000012300 Rhipsalis cassutha Nutrition 0.000 claims 1
• 241000283984 Rodentia Species 0.000 claims 1
• 102100025541 S-acyl fatty acid synthase thioesterase, medium chain Human genes 0.000 claims 1
• 208000008765 Sciatica Diseases 0.000 claims 1
• 206010039705 Scleritis Diseases 0.000 claims 1
• 244000191761 Sida cordifolia Species 0.000 claims 1
• 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
• KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims 1
• VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims 1
• UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims 1
• 101100109876 Solanum tuberosum SHKA gene Proteins 0.000 claims 1
• 206010041349 Somnolence Diseases 0.000 claims 1
• 244000300264 Spinacia oleracea Species 0.000 claims 1
• 235000009337 Spinacia oleracea Nutrition 0.000 claims 1
• 102000005782 Squalene Monooxygenase Human genes 0.000 claims 1
• 108020003891 Squalene monooxygenase Proteins 0.000 claims 1
• 241000269319 Squalius cephalus Species 0.000 claims 1
• 235000021355 Stearic acid Nutrition 0.000 claims 1
• KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims 1
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 1
• 229930006000 Sucrose Natural products 0.000 claims 1
• QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 1
• 208000032450 Surgical Shock Diseases 0.000 claims 1
• 229940126530 T cell activator Drugs 0.000 claims 1
• FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims 1
• JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 claims 1
• 229940123464 Thiazolidinedione Drugs 0.000 claims 1
• 229920002807 Thiomer Polymers 0.000 claims 1
• 229940122388 Thrombin inhibitor Drugs 0.000 claims 1
• ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 claims 1
• 102100025203 Trace amine-associated receptor 6 Human genes 0.000 claims 1
• 229920001615 Tragacanth Polymers 0.000 claims 1
• 206010052779 Transplant rejections Diseases 0.000 claims 1
• 206010044541 Traumatic shock Diseases 0.000 claims 1
• GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims 1
• OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 claims 1
• CCAZWUJBLXKBAY-ULZPOIKGSA-N Tutin Chemical compound C([C@]12[C@@H]3O[C@@H]3[C@@]3(O)[C@H]4C(=O)O[C@@H]([C@H]([C@]32C)O)[C@H]4C(=C)C)O1 CCAZWUJBLXKBAY-ULZPOIKGSA-N 0.000 claims 1
• 208000025865 Ulcer Diseases 0.000 claims 1
• XCCTYIAWTASOJW-XVFCMESISA-N Uridine-5'-Diphosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1 XCCTYIAWTASOJW-XVFCMESISA-N 0.000 claims 1
• 206010046851 Uveitis Diseases 0.000 claims 1
• 206010047050 Vascular anomaly Diseases 0.000 claims 1
• 208000035868 Vascular inflammations Diseases 0.000 claims 1
• 241000750042 Vini Species 0.000 claims 1
• 229930003779 Vitamin B12 Natural products 0.000 claims 1
• 229930003427 Vitamin E Natural products 0.000 claims 1
• 206010052428 Wound Diseases 0.000 claims 1
• 238000002441 X-ray diffraction Methods 0.000 claims 1
• 101100020289 Xenopus laevis koza gene Proteins 0.000 claims 1
• HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims 1
• DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 claims 1
• ZEEBGORNQSEQBE-UHFFFAOYSA-N [2-(3-phenylphenoxy)-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound C1(=CC(=CC=C1)OC1=NC(=CC(=C1)CN)C(F)(F)F)C1=CC=CC=C1 ZEEBGORNQSEQBE-UHFFFAOYSA-N 0.000 claims 1
• REAYFGLASQTHKB-UHFFFAOYSA-N [2-[3-(1H-pyrazol-4-yl)phenoxy]-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound N1N=CC(=C1)C=1C=C(OC2=NC(=CC(=C2)CN)C(F)(F)F)C=CC=1 REAYFGLASQTHKB-UHFFFAOYSA-N 0.000 claims 1
• SAHIZENKTPRYSN-UHFFFAOYSA-N [2-[3-(phenoxymethyl)phenoxy]-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound O(C1=CC=CC=C1)CC=1C=C(OC2=NC(=CC(=C2)CN)C(F)(F)F)C=CC=1 SAHIZENKTPRYSN-UHFFFAOYSA-N 0.000 claims 1
• ABRVLXLNVJHDRQ-UHFFFAOYSA-N [2-pyridin-3-yl-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound FC(C1=CC(=CC(=N1)C=1C=NC=CC=1)CN)(F)F ABRVLXLNVJHDRQ-UHFFFAOYSA-N 0.000 claims 1
• YQYBUJYBXOVWQW-UHFFFAOYSA-N [3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxyphenyl]-(3,4-dihydro-1H-isoquinolin-2-yl)methanone Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C=CC=1)C(=O)N1CC2=CC=CC=C2CC1 YQYBUJYBXOVWQW-UHFFFAOYSA-N 0.000 claims 1
• YKKPYMXANSSQCA-UHFFFAOYSA-N [3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxyphenyl]-(3-pyrazol-1-ylazetidin-1-yl)methanone Chemical compound N1(N=CC=C1)C1CN(C1)C(=O)C1=CC(=CC=C1)OC1=NC(=CC(=C1)CN)C(F)(F)F YKKPYMXANSSQCA-UHFFFAOYSA-N 0.000 claims 1
• PZRPBPMLSSNFOM-UHFFFAOYSA-N [4-(hydroxymethyl)phenyl]boronic acid Chemical compound OCC1=CC=C(B(O)O)C=C1 PZRPBPMLSSNFOM-UHFFFAOYSA-N 0.000 claims 1
• 206010000059 abdominal discomfort Diseases 0.000 claims 1
• 230000005856 abnormality Effects 0.000 claims 1
• GPWHDDKQSYOYBF-UHFFFAOYSA-N ac1l2u0q Chemical compound Br[Br-]Br GPWHDDKQSYOYBF-UHFFFAOYSA-N 0.000 claims 1
• 235000010489 acacia gum Nutrition 0.000 claims 1
• 239000000205 acacia gum Substances 0.000 claims 1
• GOEMGAFJFRBGGG-UHFFFAOYSA-N acebutolol Chemical compound CCCC(=O)NC1=CC=C(OCC(O)CNC(C)C)C(C(C)=O)=C1 GOEMGAFJFRBGGG-UHFFFAOYSA-N 0.000 claims 1
• 229960002122 acebutolol Drugs 0.000 claims 1
• DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Chemical group CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 claims 1
• 150000001241 acetals Chemical group 0.000 claims 1
• 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 1
• 239000003377 acid catalyst Substances 0.000 claims 1
• 230000002378 acidificating effect Effects 0.000 claims 1
• 208000038016 acute inflammation Diseases 0.000 claims 1
• 230000006022 acute inflammation Effects 0.000 claims 1
• 208000012998 acute renal failure Diseases 0.000 claims 1
• 125000002252 acyl group Chemical group 0.000 claims 1
• 230000010933 acylation Effects 0.000 claims 1
• 238000005917 acylation reaction Methods 0.000 claims 1
• 235000010419 agar Nutrition 0.000 claims 1
• 125000003158 alcohol group Chemical group 0.000 claims 1
• IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical class O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 claims 1
• DCSBSVSZJRSITC-UHFFFAOYSA-M alendronate sodium trihydrate Chemical compound O.O.O.[Na+].NCCCC(O)(P(O)(O)=O)P(O)([O-])=O DCSBSVSZJRSITC-UHFFFAOYSA-M 0.000 claims 1
• 229960004343 alendronic acid Drugs 0.000 claims 1
• 235000010443 alginic acid Nutrition 0.000 claims 1
• 229920000615 alginic acid Polymers 0.000 claims 1
• 239000000783 alginic acid Substances 0.000 claims 1
• 229960001126 alginic acid Drugs 0.000 claims 1
• 150000004781 alginic acids Chemical class 0.000 claims 1
• 125000001931 aliphatic group Chemical group 0.000 claims 1
• 229910052783 alkali metal Inorganic materials 0.000 claims 1
• 229910001413 alkali metal ion Inorganic materials 0.000 claims 1
• 150000001340 alkali metals Chemical class 0.000 claims 1
• 229910052784 alkaline earth metal Inorganic materials 0.000 claims 1
• 229910001420 alkaline earth metal ion Inorganic materials 0.000 claims 1
• 150000003973 alkyl amines Chemical class 0.000 claims 1
• 150000005215 alkyl ethers Chemical class 0.000 claims 1
• 125000005037 alkyl phenyl group Chemical group 0.000 claims 1
• 125000005360 alkyl sulfoxide group Chemical group 0.000 claims 1
• 125000004414 alkyl thio group Chemical group 0.000 claims 1
• 230000029936 alkylation Effects 0.000 claims 1
• OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 claims 1
• 230000009285 allergic inflammation Effects 0.000 claims 1
• BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims 1
• 229910052782 aluminium Inorganic materials 0.000 claims 1
• XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims 1
• WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims 1
• 238000010640 amide synthesis reaction Methods 0.000 claims 1
• 239000003194 amino acid receptor blocking agent Substances 0.000 claims 1
• 235000019270 ammonium chloride Nutrition 0.000 claims 1
• BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 claims 1
• 229910052921 ammonium sulfate Inorganic materials 0.000 claims 1
• 235000011130 ammonium sulphate Nutrition 0.000 claims 1
• 230000003321 amplification Effects 0.000 claims 1
• 230000036783 anaphylactic response Effects 0.000 claims 1
• 208000003455 anaphylaxis Diseases 0.000 claims 1
• 238000002399 angioplasty Methods 0.000 claims 1
• 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims 1
• 150000008064 anhydrides Chemical class 0.000 claims 1
• ZRALSGWEFCBTJO-UHFFFAOYSA-N anhydrous guanidine Natural products NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 claims 1
• 150000001450 anions Chemical class 0.000 claims 1
• 230000002785 anti-thrombosis Effects 0.000 claims 1
• 239000002220 antihypertensive agent Substances 0.000 claims 1
• 229940127088 antihypertensive drug Drugs 0.000 claims 1
• 239000002246 antineoplastic agent Substances 0.000 claims 1
• 230000003078 antioxidant effect Effects 0.000 claims 1
• 229940027983 antiseptic and disinfectant quaternary ammonium compound Drugs 0.000 claims 1
• 229960004676 antithrombotic agent Drugs 0.000 claims 1
• 239000003443 antiviral agent Substances 0.000 claims 1
• 235000019789 appetite Nutrition 0.000 claims 1
• 230000036528 appetite Effects 0.000 claims 1
• 239000012062 aqueous buffer Substances 0.000 claims 1
• 239000008365 aqueous carrier Substances 0.000 claims 1
• KXNPVXPOPUZYGB-XYVMCAHJSA-N argatroban Chemical compound OC(=O)[C@H]1C[C@H](C)CCN1C(=O)[C@H](CCCN=C(N)N)NS(=O)(=O)C1=CC=CC2=C1NC[C@H](C)C2 KXNPVXPOPUZYGB-XYVMCAHJSA-N 0.000 claims 1
• 229960003856 argatroban Drugs 0.000 claims 1
• 230000006793 arrhythmia Effects 0.000 claims 1
• 206010003119 arrhythmia Diseases 0.000 claims 1
• 229940097776 arthrotec Drugs 0.000 claims 1
• 125000005362 aryl sulfone group Chemical group 0.000 claims 1
• 125000005361 aryl sulfoxide group Chemical group 0.000 claims 1
• 125000005110 aryl thio group Chemical group 0.000 claims 1
• 125000004104 aryloxy group Chemical group 0.000 claims 1
• 229940072224 asacol Drugs 0.000 claims 1
• 229940072107 ascorbate Drugs 0.000 claims 1
• 238000003556 assay Methods 0.000 claims 1
• 239000000305 astragalus gummifer gum Substances 0.000 claims 1
• 210000001130 astrocyte Anatomy 0.000 claims 1
• 229960002274 atenolol Drugs 0.000 claims 1
• 201000008937 atopic dermatitis Diseases 0.000 claims 1
• HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 claims 1
• GFZWHAAOIVMHOI-UHFFFAOYSA-N azetidine-3-carboxylic acid Chemical compound OC(=O)C1CNC1 GFZWHAAOIVMHOI-UHFFFAOYSA-N 0.000 claims 1
• 210000003719 b-lymphocyte Anatomy 0.000 claims 1
• 229960000686 benzalkonium chloride Drugs 0.000 claims 1
• SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 claims 1
• 229940092714 benzenesulfonic acid Drugs 0.000 claims 1
• 125000004601 benzofurazanyl group Chemical group N1=C2C(=NO1)C(=CC=C2)* 0.000 claims 1
• CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims 1
• GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 claims 1
• 235000013734 beta-carotene Nutrition 0.000 claims 1
• 239000011648 beta-carotene Substances 0.000 claims 1
• TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 claims 1
• 229960002747 betacarotene Drugs 0.000 claims 1
• 229940110331 bextra Drugs 0.000 claims 1
• 239000003613 bile acid Substances 0.000 claims 1
• 239000011230 binding agent Substances 0.000 claims 1
• 230000033228 biological regulation Effects 0.000 claims 1
• 230000037396 body weight Effects 0.000 claims 1
• 238000009835 boiling Methods 0.000 claims 1
• 238000006664 bond formation reaction Methods 0.000 claims 1
• 229910000085 borane Inorganic materials 0.000 claims 1
• 229910021538 borax Inorganic materials 0.000 claims 1
• 235000010338 boric acid Nutrition 0.000 claims 1
• UWTDFICHZKXYAC-UHFFFAOYSA-N boron;oxolane Chemical compound [B].C1CCOC1 UWTDFICHZKXYAC-UHFFFAOYSA-N 0.000 claims 1
• 208000029028 brain injury Diseases 0.000 claims 1
• 210000000481 breast Anatomy 0.000 claims 1
• 230000031709 bromination Effects 0.000 claims 1
• 238000005893 bromination reaction Methods 0.000 claims 1
• 125000001246 bromo group Chemical group Br* 0.000 claims 1
• 210000000621 bronchi Anatomy 0.000 claims 1
• 239000007853 buffer solution Substances 0.000 claims 1
• 239000008366 buffered solution Substances 0.000 claims 1
• 239000006172 buffering agent Substances 0.000 claims 1
• KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims 1
• 125000004369 butenyl group Chemical group C(=CCC)* 0.000 claims 1
• 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
• FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 claims 1
• 229910000024 caesium carbonate Inorganic materials 0.000 claims 1
• AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 claims 1
• 239000000920 calcium hydroxide Substances 0.000 claims 1
• 229910001861 calcium hydroxide Inorganic materials 0.000 claims 1
• 239000003710 calcium ionophore Substances 0.000 claims 1
• 239000001506 calcium phosphate Substances 0.000 claims 1
• 229910000389 calcium phosphate Inorganic materials 0.000 claims 1
• 235000011010 calcium phosphates Nutrition 0.000 claims 1
• 159000000007 calcium salts Chemical class 0.000 claims 1
• 208000035269 cancer or benign tumor Diseases 0.000 claims 1
• SGZAIDDFHDDFJU-UHFFFAOYSA-N candesartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SGZAIDDFHDDFJU-UHFFFAOYSA-N 0.000 claims 1
• 229960000932 candesartan Drugs 0.000 claims 1
• 210000001043 capillary endothelial cell Anatomy 0.000 claims 1
• FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 claims 1
• 229960000830 captopril Drugs 0.000 claims 1
• 150000004657 carbamic acid derivatives Chemical group 0.000 claims 1
• 229960001631 carbomer Drugs 0.000 claims 1
• 150000001721 carbon Chemical group 0.000 claims 1
• 239000001569 carbon dioxide Substances 0.000 claims 1
• 229910002092 carbon dioxide Inorganic materials 0.000 claims 1
• 229960004424 carbon dioxide Drugs 0.000 claims 1
• 150000004653 carbonic acids Chemical class 0.000 claims 1
• 235000010948 carboxy methyl cellulose Nutrition 0.000 claims 1
• 150000001735 carboxylic acids Chemical class 0.000 claims 1
• 239000008112 carboxymethyl-cellulose Substances 0.000 claims 1
• 239000012159 carrier gas Substances 0.000 claims 1
• 239000004359 castor oil Substances 0.000 claims 1
• 235000019438 castor oil Nutrition 0.000 claims 1
• 150000001768 cations Chemical class 0.000 claims 1
• 229940047495 celebrex Drugs 0.000 claims 1
• 230000020411 cell activation Effects 0.000 claims 1
• 230000010261 cell growth Effects 0.000 claims 1
• 230000001413 cellular effect Effects 0.000 claims 1
• 235000010980 cellulose Nutrition 0.000 claims 1
• 229920002678 cellulose Polymers 0.000 claims 1
• 239000001913 cellulose Substances 0.000 claims 1
• 239000002738 chelating agent Substances 0.000 claims 1
• 239000003638 chemical reducing agent Substances 0.000 claims 1
• 230000035605 chemotaxis Effects 0.000 claims 1
• 238000002512 chemotherapy Methods 0.000 claims 1
• 239000012829 chemotherapy agent Substances 0.000 claims 1
• 229910052801 chlorine Inorganic materials 0.000 claims 1
• 235000019398 chlorine dioxide Nutrition 0.000 claims 1
• WBLIXGSTEMXDSM-UHFFFAOYSA-N chloromethane Chemical compound Cl[CH2] WBLIXGSTEMXDSM-UHFFFAOYSA-N 0.000 claims 1
• 235000012000 cholesterol Nutrition 0.000 claims 1
• 230000001906 cholesterol absorption Effects 0.000 claims 1
• 210000000349 chromosome Anatomy 0.000 claims 1
• 208000037893 chronic inflammatory disorder Diseases 0.000 claims 1
• 235000013985 cinnamic acid Nutrition 0.000 claims 1
• 229930016911 cinnamic acid Natural products 0.000 claims 1
• 229960001284 citicoline Drugs 0.000 claims 1
• 229960004106 citric acid Drugs 0.000 claims 1
• 238000011281 clinical therapy Methods 0.000 claims 1
• KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 claims 1
• 229960001214 clofibrate Drugs 0.000 claims 1
• 239000011248 coating agent Substances 0.000 claims 1
• AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 claims 1
• 206010009887 colitis Diseases 0.000 claims 1
• 229920001436 collagen Polymers 0.000 claims 1
• 238000004891 communication Methods 0.000 claims 1
• 238000005056 compaction Methods 0.000 claims 1
• 238000013329 compounding Methods 0.000 claims 1
• 238000009833 condensation Methods 0.000 claims 1
• 230000005494 condensation Effects 0.000 claims 1
• 229920001577 copolymer Polymers 0.000 claims 1
• 239000008120 corn starch Substances 0.000 claims 1
• 229940099112 cornstarch Drugs 0.000 claims 1
• 230000002596 correlated effect Effects 0.000 claims 1
• 230000000875 corresponding effect Effects 0.000 claims 1
• 238000005859 coupling reaction Methods 0.000 claims 1
• 229940111134 coxibs Drugs 0.000 claims 1
• 229960001681 croscarmellose sodium Drugs 0.000 claims 1
• 229920006037 cross link polymer Polymers 0.000 claims 1
• 238000006880 cross-coupling reaction Methods 0.000 claims 1
• 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims 1
• 235000000639 cyanocobalamin Nutrition 0.000 claims 1
• 239000011666 cyanocobalamin Substances 0.000 claims 1
• 229960002104 cyanocobalamin Drugs 0.000 claims 1
• WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 claims 1
• 229960000729 cyclandelate Drugs 0.000 claims 1
• 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
• 229940097362 cyclodextrins Drugs 0.000 claims 1
• JMFVWNKPLURQMI-UHFFFAOYSA-N cyclopentyl carbamate Chemical compound NC(=O)OC1CCCC1 JMFVWNKPLURQMI-UHFFFAOYSA-N 0.000 claims 1
• WLACEWSOCRKWLJ-UHFFFAOYSA-N cycloprop-2-yn-1-amine Chemical compound C1(C#C1)N WLACEWSOCRKWLJ-UHFFFAOYSA-N 0.000 claims 1
• 210000000805 cytoplasm Anatomy 0.000 claims 1
• 230000001086 cytosolic effect Effects 0.000 claims 1
• 229940127089 cytotoxic agent Drugs 0.000 claims 1
• 230000007123 defense Effects 0.000 claims 1
• 230000002950 deficient Effects 0.000 claims 1
• 208000018180 degenerative disc disease Diseases 0.000 claims 1
• 230000018044 dehydration Effects 0.000 claims 1
• 238000006297 dehydration reaction Methods 0.000 claims 1
• 231100000868 delusion Toxicity 0.000 claims 1
• 230000001627 detrimental effect Effects 0.000 claims 1
• 229960003957 dexamethasone Drugs 0.000 claims 1
• UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 1
• 229960000633 dextran sulfate Drugs 0.000 claims 1
• 239000008121 dextrose Substances 0.000 claims 1
• 206010012601 diabetes mellitus Diseases 0.000 claims 1
• 125000002576 diazepinyl group Chemical group N1N=C(C=CC=C1)* 0.000 claims 1
• PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 claims 1
• 235000019404 dichlorodifluoromethane Nutrition 0.000 claims 1
• 229940042935 dichlorodifluoromethane Drugs 0.000 claims 1
• 229940087091 dichlorotetrafluoroethane Drugs 0.000 claims 1
• ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 claims 1
• 208000010643 digestive system disease Diseases 0.000 claims 1
• 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 claims 1
• 125000005047 dihydroimidazolyl group Chemical group N1(CNC=C1)* 0.000 claims 1
• 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 claims 1
• HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 claims 1
• 229960004166 diltiazem Drugs 0.000 claims 1
• SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 claims 1
• 150000002013 dioxins Chemical class 0.000 claims 1
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 claims 1
• 150000002016 disaccharides Chemical class 0.000 claims 1
• 230000006806 disease prevention Effects 0.000 claims 1
• 239000007884 disintegrant Substances 0.000 claims 1
• 230000009189 diving Effects 0.000 claims 1
• MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 claims 1
• 229940043264 dodecyl sulfate Drugs 0.000 claims 1
• 239000006196 drop Substances 0.000 claims 1
• 239000000890 drug combination Substances 0.000 claims 1
• 238000012377 drug delivery Methods 0.000 claims 1
• 239000003118 drug derivative Substances 0.000 claims 1
• 230000008482 dysregulation Effects 0.000 claims 1
• 206010013990 dysuria Diseases 0.000 claims 1
• 210000005069 ears Anatomy 0.000 claims 1
• QELUYTUMUWHWMC-UHFFFAOYSA-N edaravone Chemical compound O=C1CC(C)=NN1C1=CC=CC=C1 QELUYTUMUWHWMC-UHFFFAOYSA-N 0.000 claims 1
• 229950009041 edaravone Drugs 0.000 claims 1
• 238000001962 electrophoresis Methods 0.000 claims 1
• 238000004945 emulsification Methods 0.000 claims 1
• 238000003821 enantio-separation Methods 0.000 claims 1
• 238000005538 encapsulation Methods 0.000 claims 1
• 230000002124 endocrine Effects 0.000 claims 1
• 210000004696 endometrium Anatomy 0.000 claims 1
• 210000002472 endoplasmic reticulum Anatomy 0.000 claims 1
• 230000003511 endothelial effect Effects 0.000 claims 1
• ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 claims 1
• 210000003038 endothelium Anatomy 0.000 claims 1
• 231100000284 endotoxic Toxicity 0.000 claims 1
• 230000002346 endotoxic effect Effects 0.000 claims 1
• 238000006911 enzymatic reaction Methods 0.000 claims 1
• 230000002327 eosinophilic effect Effects 0.000 claims 1
• 229960004563 eprosartan Drugs 0.000 claims 1
• OROAFUQRIXKEMV-LDADJPATSA-N eprosartan Chemical compound C=1C=C(C(O)=O)C=CC=1CN1C(CCCC)=NC=C1\C=C(C(O)=O)/CC1=CC=CS1 OROAFUQRIXKEMV-LDADJPATSA-N 0.000 claims 1
• 229960003745 esmolol Drugs 0.000 claims 1
• AQNDDEOPVVGCPG-UHFFFAOYSA-N esmolol Chemical compound COC(=O)CCC1=CC=C(OCC(O)CNC(C)C)C=C1 AQNDDEOPVVGCPG-UHFFFAOYSA-N 0.000 claims 1
• AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 claims 1
• DQYBDCGIPTYXML-UHFFFAOYSA-N ethoxyethane;hydrate Chemical compound O.CCOCC DQYBDCGIPTYXML-UHFFFAOYSA-N 0.000 claims 1
• CJAONIOAQZUHPN-KKLWWLSJSA-N ethyl 12-[[2-[(2r,3r)-3-[2-[(12-ethoxy-12-oxododecyl)-methylamino]-2-oxoethoxy]butan-2-yl]oxyacetyl]-methylamino]dodecanoate Chemical compound CCOC(=O)CCCCCCCCCCCN(C)C(=O)CO[C@H](C)[C@@H](C)OCC(=O)N(C)CCCCCCCCCCCC(=O)OCC CJAONIOAQZUHPN-KKLWWLSJSA-N 0.000 claims 1
• LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 claims 1
• 229940093471 ethyl oleate Drugs 0.000 claims 1
• LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 1
• PHTXVQQRWJXYPP-UHFFFAOYSA-N ethyltrifluoromethylaminoindane Chemical compound C1=C(C(F)(F)F)C=C2CC(NCC)CC2=C1 PHTXVQQRWJXYPP-UHFFFAOYSA-N 0.000 claims 1
• 238000011156 evaluation Methods 0.000 claims 1
• 230000005284 excitation Effects 0.000 claims 1
• 230000029142 excretion Effects 0.000 claims 1
• 230000001747 exhibiting effect Effects 0.000 claims 1
• 230000036251 extravasation Effects 0.000 claims 1
• 210000003414 extremity Anatomy 0.000 claims 1
• OLNTVTPDXPETLC-XPWALMASSA-N ezetimibe Chemical compound N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 OLNTVTPDXPETLC-XPWALMASSA-N 0.000 claims 1
• 229960000815 ezetimibe Drugs 0.000 claims 1
• 150000004665 fatty acids Chemical class 0.000 claims 1
• 230000002349 favourable effect Effects 0.000 claims 1
• RZTAMFZIAATZDJ-UHFFFAOYSA-N felodipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-UHFFFAOYSA-N 0.000 claims 1
• 210000001105 femoral artery Anatomy 0.000 claims 1
• 229940012952 fibrinogen Drugs 0.000 claims 1
• 239000002319 fibrinogen receptor antagonist Substances 0.000 claims 1
• 230000003176 fibrotic effect Effects 0.000 claims 1
• 229960004177 filgrastim Drugs 0.000 claims 1
• 239000012467 final product Substances 0.000 claims 1
• 238000001595 flow curve Methods 0.000 claims 1
• 239000006260 foam Substances 0.000 claims 1
• 229960000304 folic acid Drugs 0.000 claims 1
• 235000019152 folic acid Nutrition 0.000 claims 1
• 239000011724 folic acid Substances 0.000 claims 1
• 239000001530 fumaric acid Substances 0.000 claims 1
• 238000007306 functionalization reaction Methods 0.000 claims 1
• 125000003838 furazanyl group Chemical group 0.000 claims 1
• WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims 1
• 208000018685 gastrointestinal system disease Diseases 0.000 claims 1
• 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
• 238000007429 general method Methods 0.000 claims 1
• 239000000174 gluconic acid Substances 0.000 claims 1
• 235000012208 gluconic acid Nutrition 0.000 claims 1
• 239000008103 glucose Substances 0.000 claims 1
• 239000004220 glutamic acid Substances 0.000 claims 1
• 235000013922 glutamic acid Nutrition 0.000 claims 1
• ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims 1
• 150000002334 glycols Chemical class 0.000 claims 1
• 238000000227 grinding Methods 0.000 claims 1
• 239000003102 growth factor Substances 0.000 claims 1
• 229940093915 gynecological organic acid Drugs 0.000 claims 1
• 150000004820 halides Chemical class 0.000 claims 1
• 125000000262 haloalkenyl group Chemical group 0.000 claims 1
• 125000000232 haloalkynyl group Chemical group 0.000 claims 1
• 208000018578 heart valve disease Diseases 0.000 claims 1
• 230000000004 hemodynamic effect Effects 0.000 claims 1
• 229960002897 heparin Drugs 0.000 claims 1
• 229920000669 heparin Polymers 0.000 claims 1
• 239000002554 heparinoid Substances 0.000 claims 1
• 229940025770 heparinoids Drugs 0.000 claims 1
• 125000000592 heterocycloalkyl group Chemical group 0.000 claims 1
• BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 claims 1
• 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
• 238000004128 high performance liquid chromatography Methods 0.000 claims 1
• 235000012907 honey Nutrition 0.000 claims 1
• 102000056137 human PPARG Human genes 0.000 claims 1
• 239000003906 humectant Substances 0.000 claims 1
• 150000002429 hydrazines Chemical class 0.000 claims 1
• 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 1
• 230000007062 hydrolysis Effects 0.000 claims 1
• 230000003301 hydrolyzing effect Effects 0.000 claims 1
• 229920001600 hydrophobic polymer Polymers 0.000 claims 1
• WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims 1
• 208000013403 hyperactivity Diseases 0.000 claims 1
• 230000002390 hyperplastic effect Effects 0.000 claims 1
• 230000001969 hypertrophic effect Effects 0.000 claims 1
• 230000007954 hypoxia Effects 0.000 claims 1
• 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 claims 1
• 125000003037 imidazol-2-yl group Chemical group [H]N1C([*])=NC([H])=C1[H] 0.000 claims 1
• 125000002140 imidazol-4-yl group Chemical group [H]N1C([H])=NC([*])=C1[H] 0.000 claims 1
• YAMHXTCMCPHKLN-UHFFFAOYSA-N imidazolidin-2-one Chemical compound O=C1NCCN1 YAMHXTCMCPHKLN-UHFFFAOYSA-N 0.000 claims 1
• 150000008624 imidazolidinones Chemical class 0.000 claims 1
• 125000001841 imino group Chemical group [H]N=* 0.000 claims 1
• 239000012729 immediate-release (IR) formulation Substances 0.000 claims 1
• 230000001900 immune effect Effects 0.000 claims 1
• 238000003018 immunoassay Methods 0.000 claims 1
• 238000002513 implantation Methods 0.000 claims 1
• 238000010348 incorporation Methods 0.000 claims 1
• 125000002249 indol-2-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([*])=C([H])C2=C1[H] 0.000 claims 1
• 239000000411 inducer Substances 0.000 claims 1
• 230000001939 inductive effect Effects 0.000 claims 1
• 230000002458 infectious effect Effects 0.000 claims 1
• 210000004969 inflammatory cell Anatomy 0.000 claims 1
• 230000028709 inflammatory response Effects 0.000 claims 1
• 238000002329 infrared spectrum Methods 0.000 claims 1
• 229940028885 interleukin-4 Drugs 0.000 claims 1
• 229940100601 interleukin-6 Drugs 0.000 claims 1
• 208000021600 intervertebral disc degenerative disease Diseases 0.000 claims 1
• 210000000936 intestine Anatomy 0.000 claims 1
• 238000007918 intramuscular administration Methods 0.000 claims 1
• 238000010255 intramuscular injection Methods 0.000 claims 1
• 239000007927 intramuscular injection Substances 0.000 claims 1
• 238000007913 intrathecal administration Methods 0.000 claims 1
• 238000007914 intraventricular administration Methods 0.000 claims 1
• PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims 1
• INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 claims 1
• 229960002198 irbesartan Drugs 0.000 claims 1
• YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 claims 1
• 230000007794 irritation Effects 0.000 claims 1
• 239000012948 isocyanate Substances 0.000 claims 1
• 125000001261 isocyanato group Chemical group *N=C=O 0.000 claims 1
• 125000005956 isoquinolyl group Chemical group 0.000 claims 1
• 125000001810 isothiocyanato group Chemical group *N=C=S 0.000 claims 1
• 239000010977 jade Substances 0.000 claims 1
• 235000015110 jellies Nutrition 0.000 claims 1
• 239000008274 jelly Substances 0.000 claims 1
• 210000001503 joint Anatomy 0.000 claims 1
• 206010023332 keratitis Diseases 0.000 claims 1
• 201000010666 keratoconjunctivitis Diseases 0.000 claims 1
• 229940043355 kinase inhibitor Drugs 0.000 claims 1
• 238000011813 knockout mouse model Methods 0.000 claims 1
• 229960001632 labetalol Drugs 0.000 claims 1
• 239000004310 lactic acid Substances 0.000 claims 1
• FPKOGTAFKSLZLD-FQEVSTJZSA-N lamifiban Chemical compound C1=CC(C(=N)N)=CC=C1C(=O)N[C@H](C(=O)N1CCC(CC1)OCC(O)=O)CC1=CC=C(O)C=C1 FPKOGTAFKSLZLD-FQEVSTJZSA-N 0.000 claims 1
• 229950003178 lamifiban Drugs 0.000 claims 1
• 210000000867 larynx Anatomy 0.000 claims 1
• 231100000636 lethal dose Toxicity 0.000 claims 1
• 208000032839 leukemia Diseases 0.000 claims 1
• 239000000865 liniment Substances 0.000 claims 1
• 239000006193 liquid solution Substances 0.000 claims 1
• 239000006194 liquid suspension Substances 0.000 claims 1
• 238000006138 lithiation reaction Methods 0.000 claims 1
• 210000005229 liver cell Anatomy 0.000 claims 1
• 230000008338 local blood flow Effects 0.000 claims 1
• 238000011866 long-term treatment Methods 0.000 claims 1
• 239000006210 lotion Substances 0.000 claims 1
• 239000000314 lubricant Substances 0.000 claims 1
• 238000013123 lung function test Methods 0.000 claims 1
• 239000001115 mace Substances 0.000 claims 1
• 239000011777 magnesium Substances 0.000 claims 1
• 229910052749 magnesium Inorganic materials 0.000 claims 1
• 239000001095 magnesium carbonate Substances 0.000 claims 1
• 235000014380 magnesium carbonate Nutrition 0.000 claims 1
• ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 claims 1
• 229910000021 magnesium carbonate Inorganic materials 0.000 claims 1
• 159000000003 magnesium salts Chemical class 0.000 claims 1
• 235000019359 magnesium stearate Nutrition 0.000 claims 1
• VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims 1
• 239000011976 maleic acid Substances 0.000 claims 1
• 239000001630 malic acid Substances 0.000 claims 1
• 235000011090 malic acid Nutrition 0.000 claims 1
• 229960002510 mandelic acid Drugs 0.000 claims 1
• 239000000594 mannitol Substances 0.000 claims 1
• 235000010355 mannitol Nutrition 0.000 claims 1
• 238000004949 mass spectrometry Methods 0.000 claims 1
• 239000011159 matrix material Substances 0.000 claims 1
• 238000002483 medication Methods 0.000 claims 1
• 201000001441 melanoma Diseases 0.000 claims 1
• 229960004640 memantine Drugs 0.000 claims 1
• LDDHMLJTFXJGPI-UHFFFAOYSA-N memantine hydrochloride Chemical compound Cl.C1C(C2)CC3(C)CC1(C)CC2(N)C3 LDDHMLJTFXJGPI-UHFFFAOYSA-N 0.000 claims 1
• 238000003328 mesylation reaction Methods 0.000 claims 1
• 238000006241 metabolic reaction Methods 0.000 claims 1
• 229910021645 metal ion Inorganic materials 0.000 claims 1
• 230000001394 metastastic effect Effects 0.000 claims 1
• 206010061289 metastatic neoplasm Diseases 0.000 claims 1
• QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 claims 1
• WDWDWGRYHDPSDS-UHFFFAOYSA-N methanimine Chemical compound N=C WDWDWGRYHDPSDS-UHFFFAOYSA-N 0.000 claims 1
• 229930182817 methionine Natural products 0.000 claims 1
• 229920000609 methyl cellulose Polymers 0.000 claims 1
• WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 claims 1
• 230000011987 methylation Effects 0.000 claims 1
• 238000007069 methylation reaction Methods 0.000 claims 1
• 235000010981 methylcellulose Nutrition 0.000 claims 1
• 239000001923 methylcellulose Substances 0.000 claims 1
• GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 claims 1
• 229960002237 metoprolol Drugs 0.000 claims 1
• IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 claims 1
• 239000000693 micelle Substances 0.000 claims 1
• 230000000813 microbial effect Effects 0.000 claims 1
• 235000019813 microcrystalline cellulose Nutrition 0.000 claims 1
• 239000008108 microcrystalline cellulose Substances 0.000 claims 1
• 229940016286 microcrystalline cellulose Drugs 0.000 claims 1
• 150000007522 mineralic acids Chemical class 0.000 claims 1
• 231100000324 minimal toxicity Toxicity 0.000 claims 1
• 239000003607 modifier Substances 0.000 claims 1
• 150000002772 monosaccharides Chemical class 0.000 claims 1
• PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 claims 1
• 150000002780 morpholines Chemical class 0.000 claims 1
• 238000010172 mouse model Methods 0.000 claims 1
• 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 claims 1
• 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
• FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 claims 1
• VWPOSFSPZNDTMJ-UCWKZMIHSA-N nadolol Chemical compound C1[C@@H](O)[C@@H](O)CC2=C1C=CC=C2OCC(O)CNC(C)(C)C VWPOSFSPZNDTMJ-UCWKZMIHSA-N 0.000 claims 1
• 229960004255 nadolol Drugs 0.000 claims 1
• KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 claims 1
• 230000001338 necrotic effect Effects 0.000 claims 1
• 210000000653 nervous system Anatomy 0.000 claims 1
• 230000000926 neurological effect Effects 0.000 claims 1
• 201000001119 neuropathy Diseases 0.000 claims 1
• 230000007823 neuropathy Effects 0.000 claims 1
• 239000004090 neuroprotective agent Substances 0.000 claims 1
• 235000001968 nicotinic acid Nutrition 0.000 claims 1
• 229960003512 nicotinic acid Drugs 0.000 claims 1
• 239000011664 nicotinic acid Substances 0.000 claims 1
• HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 claims 1
• 229960001597 nifedipine Drugs 0.000 claims 1
• FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 claims 1
• 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
• ZHCAAFJSYLFLPX-UHFFFAOYSA-N nitrocyclohexatriene Chemical group [O-][N+](=O)C1=CC=C=C[CH]1 ZHCAAFJSYLFLPX-UHFFFAOYSA-N 0.000 claims 1
• 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
• QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
• 239000002764 nociceptin receptor antagonist Substances 0.000 claims 1
• 239000012740 non-selective inhibitor Substances 0.000 claims 1
• 239000012457 nonaqueous media Substances 0.000 claims 1
• 210000001331 nose Anatomy 0.000 claims 1
• 238000003199 nucleic acid amplification method Methods 0.000 claims 1
• 230000000269 nucleophilic effect Effects 0.000 claims 1
• QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 1
• OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims 1
• 229920004905 octoxynol-10 Polymers 0.000 claims 1
• 229920004914 octoxynol-40 Polymers 0.000 claims 1
• 239000012053 oil suspension Substances 0.000 claims 1
• 239000002674 ointment Substances 0.000 claims 1
• 229920001542 oligosaccharide Polymers 0.000 claims 1
• 150000002482 oligosaccharides Chemical class 0.000 claims 1
• 230000000771 oncological effect Effects 0.000 claims 1
• 230000003287 optical effect Effects 0.000 claims 1
• 235000005985 organic acids Nutrition 0.000 claims 1
• 125000001181 organosilyl group Chemical group [SiH3]* 0.000 claims 1
• 231100000927 organotoxic Toxicity 0.000 claims 1
• 208000005368 osteomalacia Diseases 0.000 claims 1
• 210000001672 ovary Anatomy 0.000 claims 1
• 125000003551 oxepanyl group Chemical group 0.000 claims 1
• 125000003566 oxetanyl group Chemical group 0.000 claims 1
• 230000001590 oxidative effect Effects 0.000 claims 1
• 238000006213 oxygenation reaction Methods 0.000 claims 1
• 229950003837 ozagrel Drugs 0.000 claims 1
• 239000003002 pH adjusting agent Substances 0.000 claims 1
• 239000006179 pH buffering agent Substances 0.000 claims 1
• 238000004806 packaging method and process Methods 0.000 claims 1
• 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
• 229960002131 palonosetron Drugs 0.000 claims 1
• CPZBLNMUGSZIPR-NVXWUHKLSA-N palonosetron Chemical compound C1N(CC2)CCC2[C@@H]1N1C(=O)C(C=CC=C2CCC3)=C2[C@H]3C1 CPZBLNMUGSZIPR-NVXWUHKLSA-N 0.000 claims 1
• 210000000496 pancreas Anatomy 0.000 claims 1
• 239000006072 paste Substances 0.000 claims 1
• 230000001575 pathological effect Effects 0.000 claims 1
• 230000009054 pathological process Effects 0.000 claims 1
• 230000007170 pathology Effects 0.000 claims 1
• 210000004197 pelvis Anatomy 0.000 claims 1
• 125000001147 pentyl group Chemical group C(CCCC)* 0.000 claims 1
• 208000022719 perennial allergic rhinitis Diseases 0.000 claims 1
• 125000005010 perfluoroalkyl group Chemical group 0.000 claims 1
• 230000000737 periodic effect Effects 0.000 claims 1
• 210000001428 peripheral nervous system Anatomy 0.000 claims 1
• 230000002085 persistent effect Effects 0.000 claims 1
• 235000019271 petrolatum Nutrition 0.000 claims 1
• 239000008177 pharmaceutical agent Substances 0.000 claims 1
• 230000000144 pharmacologic effect Effects 0.000 claims 1
• 210000003800 pharynx Anatomy 0.000 claims 1
• 150000002989 phenols Chemical class 0.000 claims 1
• YKWNDAOEJQMLGH-UHFFFAOYSA-N phenyl 2,2-diphenylacetate Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)C(=O)OC1=CC=CC=C1 YKWNDAOEJQMLGH-UHFFFAOYSA-N 0.000 claims 1
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
• 239000010452 phosphate Substances 0.000 claims 1
• 239000002953 phosphate buffered saline Substances 0.000 claims 1
• 229910052698 phosphorus Inorganic materials 0.000 claims 1
• 239000011574 phosphorus Substances 0.000 claims 1
• FAIAAWCVCHQXDN-UHFFFAOYSA-N phosphorus trichloride Chemical compound ClP(Cl)Cl FAIAAWCVCHQXDN-UHFFFAOYSA-N 0.000 claims 1
• 239000003757 phosphotransferase inhibitor Substances 0.000 claims 1
• 239000000049 pigment Substances 0.000 claims 1
• JZQKKSLKJUAGIC-UHFFFAOYSA-N pindolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=C1C=CN2 JZQKKSLKJUAGIC-UHFFFAOYSA-N 0.000 claims 1
• 229960002508 pindolol Drugs 0.000 claims 1
• 229960005095 pioglitazone Drugs 0.000 claims 1
• 150000004885 piperazines Chemical class 0.000 claims 1
• 125000004193 piperazinyl group Chemical group 0.000 claims 1
• 150000003053 piperidines Chemical class 0.000 claims 1
• IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 claims 1
• 239000004014 plasticizer Substances 0.000 claims 1
• 231100000614 poison Toxicity 0.000 claims 1
• 229920003229 poly(methyl methacrylate) Polymers 0.000 claims 1
• 229920002401 polyacrylamide Polymers 0.000 claims 1
• 208000030428 polyarticular arthritis Diseases 0.000 claims 1
• 229950005134 polycarbophil Drugs 0.000 claims 1
• 229940068918 polyethylene glycol 400 Drugs 0.000 claims 1
• 229920000151 polyglycol Polymers 0.000 claims 1
• 239000010695 polyglycol Substances 0.000 claims 1
• 239000004926 polymethyl methacrylate Substances 0.000 claims 1
• 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims 1
• 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims 1
• 229920000136 polysorbate Polymers 0.000 claims 1
• 229950008882 polysorbate Drugs 0.000 claims 1
• 229940068977 polysorbate 20 Drugs 0.000 claims 1
• 235000020777 polyunsaturated fatty acids Nutrition 0.000 claims 1
• 239000011591 potassium Substances 0.000 claims 1
• 229910052700 potassium Inorganic materials 0.000 claims 1
• XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims 1
• 239000001103 potassium chloride Substances 0.000 claims 1
• 235000011164 potassium chloride Nutrition 0.000 claims 1
• WSHYKIAQCMIPTB-UHFFFAOYSA-M potassium;2-oxo-3-(3-oxo-1-phenylbutyl)chromen-4-olate Chemical compound [K+].[O-]C=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 WSHYKIAQCMIPTB-UHFFFAOYSA-M 0.000 claims 1
• 229920001592 potato starch Polymers 0.000 claims 1
• 229940116317 potato starch Drugs 0.000 claims 1
• 230000003389 potentiating effect Effects 0.000 claims 1
• 229940069328 povidone Drugs 0.000 claims 1
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
• 230000002035 prolonged effect Effects 0.000 claims 1
• 125000004368 propenyl group Chemical group C(=CC)* 0.000 claims 1
• 235000019260 propionic acid Nutrition 0.000 claims 1
• AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 claims 1
• 150000003180 prostaglandins Chemical class 0.000 claims 1
• 210000002307 prostate Anatomy 0.000 claims 1
• 230000001681 protective effect Effects 0.000 claims 1
• 238000000159 protein binding assay Methods 0.000 claims 1
• 235000004252 protein component Nutrition 0.000 claims 1
• 201000009732 pulmonary eosinophilia Diseases 0.000 claims 1
• 238000009613 pulmonary function test Methods 0.000 claims 1
• 230000000541 pulsatile effect Effects 0.000 claims 1
• 210000001747 pupil Anatomy 0.000 claims 1
• XFTQRUTUGRCSGO-UHFFFAOYSA-N pyrazin-2-amine Chemical compound NC1=CN=CC=N1 XFTQRUTUGRCSGO-UHFFFAOYSA-N 0.000 claims 1
• USPWKWBDZOARPV-UHFFFAOYSA-N pyrazolidine Chemical compound C1CNNC1 USPWKWBDZOARPV-UHFFFAOYSA-N 0.000 claims 1
• 150000003218 pyrazolidines Chemical class 0.000 claims 1
• SHNUBALDGXWUJI-UHFFFAOYSA-N pyridin-2-ylmethanol Chemical compound OCC1=CC=CC=N1 SHNUBALDGXWUJI-UHFFFAOYSA-N 0.000 claims 1
• 235000008160 pyridoxine Nutrition 0.000 claims 1
• 239000011677 pyridoxine Substances 0.000 claims 1
• 150000003235 pyrrolidines Chemical class 0.000 claims 1
• 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
• 229940107700 pyruvic acid Drugs 0.000 claims 1
• 150000003856 quaternary ammonium compounds Chemical class 0.000 claims 1
• 238000010791 quenching Methods 0.000 claims 1
• IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims 1
• 230000006340 racemization Effects 0.000 claims 1
• 239000002516 radical scavenger Substances 0.000 claims 1
• 150000003254 radicals Chemical class 0.000 claims 1
• 238000003127 radioimmunoassay Methods 0.000 claims 1
• 238000011552 rat model Methods 0.000 claims 1
• 239000011541 reaction mixture Substances 0.000 claims 1
• 230000009257 reactivity Effects 0.000 claims 1
• 230000008707 rearrangement Effects 0.000 claims 1
• 230000006798 recombination Effects 0.000 claims 1
• 238000005215 recombination Methods 0.000 claims 1
• 238000011084 recovery Methods 0.000 claims 1
• 230000001105 regulatory effect Effects 0.000 claims 1
• 210000003019 respiratory muscle Anatomy 0.000 claims 1
• 230000000717 retained effect Effects 0.000 claims 1
• 230000002441 reversible effect Effects 0.000 claims 1
• 229940100486 rice starch Drugs 0.000 claims 1
• GLLPUTYLZIKEGF-HAVVHWLPSA-N ridogrel Chemical compound C=1C=CC(C(F)(F)F)=CC=1C(=N/OCCCCC(=O)O)\C1=CC=CN=C1 GLLPUTYLZIKEGF-HAVVHWLPSA-N 0.000 claims 1
• 229950006674 ridogrel Drugs 0.000 claims 1
• 238000007363 ring formation reaction Methods 0.000 claims 1
• 229960004586 rosiglitazone Drugs 0.000 claims 1
• 208000017022 seasonal allergic rhinitis Diseases 0.000 claims 1
• 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
• 238000012163 sequencing technique Methods 0.000 claims 1
• 239000008159 sesame oil Substances 0.000 claims 1
• 235000011803 sesame oil Nutrition 0.000 claims 1
• 238000009958 sewing Methods 0.000 claims 1
• 206010040560 shock Diseases 0.000 claims 1
• 230000035939 shock Effects 0.000 claims 1
• PYRLGKOKNUJQQN-UHFFFAOYSA-N silylcarbamic acid Chemical class OC(=O)N[SiH3] PYRLGKOKNUJQQN-UHFFFAOYSA-N 0.000 claims 1
• 208000017520 skin disease Diseases 0.000 claims 1
• 239000002002 slurry Substances 0.000 claims 1
• 239000000779 smoke Substances 0.000 claims 1
• 230000016160 smooth muscle contraction Effects 0.000 claims 1
• 239000001632 sodium acetate Substances 0.000 claims 1
• 235000017281 sodium acetate Nutrition 0.000 claims 1
• 229910000033 sodium borohydride Inorganic materials 0.000 claims 1
• 239000012279 sodium borohydride Substances 0.000 claims 1
• 229910000029 sodium carbonate Inorganic materials 0.000 claims 1
• 239000003195 sodium channel blocking agent Substances 0.000 claims 1
• 239000001509 sodium citrate Substances 0.000 claims 1
• NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims 1
• 235000011083 sodium citrates Nutrition 0.000 claims 1
• JVBXVOWTABLYPX-UHFFFAOYSA-L sodium dithionite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])=O JVBXVOWTABLYPX-UHFFFAOYSA-L 0.000 claims 1
• 239000012312 sodium hydride Substances 0.000 claims 1
• 229910000104 sodium hydride Inorganic materials 0.000 claims 1
• 239000001540 sodium lactate Substances 0.000 claims 1
• 235000011088 sodium lactate Nutrition 0.000 claims 1
• 229940005581 sodium lactate Drugs 0.000 claims 1
• 239000001488 sodium phosphate Substances 0.000 claims 1
• 229910000162 sodium phosphate Inorganic materials 0.000 claims 1
• 235000011008 sodium phosphates Nutrition 0.000 claims 1
• 235000010339 sodium tetraborate Nutrition 0.000 claims 1
• YPURUCMVRRNPHJ-UHFFFAOYSA-M sodium;3-[3-tert-butylsulfanyl-1-[(4-chlorophenyl)methyl]-5-(quinolin-2-ylmethoxy)indol-2-yl]-2,2-dimethylpropanoate Chemical compound [Na+].C12=CC=C(OCC=3N=C4C=CC=CC4=CC=3)C=C2C(SC(C)(C)C)=C(CC(C)(C)C([O-])=O)N1CC1=CC=C(Cl)C=C1 YPURUCMVRRNPHJ-UHFFFAOYSA-M 0.000 claims 1
• YWAFNFGRBBBSPD-OCMLZEEQSA-M sodium;[[(2r,3s,4r,5r)-5-(4-amino-2-oxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-oxidophosphoryl] 2-(trimethylazaniumyl)ethyl phosphate Chemical compound [Na+].O[C@@H]1[C@H](O)[C@@H](COP([O-])(=O)OP([O-])(=O)OCC[N+](C)(C)C)O[C@H]1N1C(=O)N=C(N)C=C1 YWAFNFGRBBBSPD-OCMLZEEQSA-M 0.000 claims 1
• 239000007901 soft capsule Substances 0.000 claims 1
• 239000012439 solid excipient Substances 0.000 claims 1
• 239000004071 soot Substances 0.000 claims 1
• 229940075554 sorbate Drugs 0.000 claims 1
• 241000894007 species Species 0.000 claims 1
• 208000010110 spontaneous platelet aggregation Diseases 0.000 claims 1
• 239000007921 spray Substances 0.000 claims 1
• 230000000087 stabilizing effect Effects 0.000 claims 1
• 239000008107 starch Substances 0.000 claims 1
• 239000008117 stearic acid Substances 0.000 claims 1
• 238000003860 storage Methods 0.000 claims 1
• 208000023516 stroke disease Diseases 0.000 claims 1
• 238000007920 subcutaneous administration Methods 0.000 claims 1
• 239000005720 sucrose Substances 0.000 claims 1
• 150000008163 sugars Chemical class 0.000 claims 1
• 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 1
• 239000002511 suppository base Substances 0.000 claims 1
• 239000004094 surface-active agent Substances 0.000 claims 1
• 230000008961 swelling Effects 0.000 claims 1
• 238000001308 synthesis method Methods 0.000 claims 1
• 229920001059 synthetic polymer Polymers 0.000 claims 1
• 239000006188 syrup Substances 0.000 claims 1
• 235000020357 syrup Nutrition 0.000 claims 1
• 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
• 229910052715 tantalum Inorganic materials 0.000 claims 1
• 239000011975 tartaric acid Substances 0.000 claims 1
• 235000002906 tartaric acid Nutrition 0.000 claims 1
• 206010043207 temporal arteritis Diseases 0.000 claims 1
• ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical group C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 claims 1
• WMXCDAVJEZZYLT-UHFFFAOYSA-N tert-butylthiol Chemical compound CC(C)(C)S WMXCDAVJEZZYLT-UHFFFAOYSA-N 0.000 claims 1
• 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 1
• 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 1
• 125000004853 tetrahydropyridinyl group Chemical class N1(CCCC=C1)* 0.000 claims 1
• 150000003530 tetrahydroquinolines Chemical class 0.000 claims 1
• 125000005958 tetrahydrothienyl group Chemical group 0.000 claims 1
• 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 claims 1
• 231100001274 therapeutic index Toxicity 0.000 claims 1
• 238000011285 therapeutic regimen Methods 0.000 claims 1
• 235000019157 thiamine Nutrition 0.000 claims 1
• KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 claims 1
• 229960003495 thiamine Drugs 0.000 claims 1
• 239000011721 thiamine Substances 0.000 claims 1
• PGAZQSBUJDVGIX-UHFFFAOYSA-N thiazepane Chemical compound C1CCNSCC1 PGAZQSBUJDVGIX-UHFFFAOYSA-N 0.000 claims 1
• 150000000325 thiazepanes Chemical class 0.000 claims 1
• 150000003548 thiazolidines Chemical class 0.000 claims 1
• 125000001583 thiepanyl group Chemical group 0.000 claims 1
• 125000002053 thietanyl group Chemical group 0.000 claims 1
• RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 claims 1
• 125000004149 thio group Chemical group *S* 0.000 claims 1
• 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 claims 1
• 125000000858 thiocyanato group Chemical group *SC#N 0.000 claims 1
• 229960004906 thiomersal Drugs 0.000 claims 1
• 229930192474 thiophene Natural products 0.000 claims 1
• IBBLKSWSCDAPIF-UHFFFAOYSA-N thiopyran Chemical compound S1C=CC=C=C1 IBBLKSWSCDAPIF-UHFFFAOYSA-N 0.000 claims 1
• DHCDFWKWKRSZHF-UHFFFAOYSA-L thiosulfate(2-) Chemical compound [O-]S([S-])(=O)=O DHCDFWKWKRSZHF-UHFFFAOYSA-L 0.000 claims 1
• 239000003868 thrombin inhibitor Substances 0.000 claims 1
• RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 claims 1
• 210000001685 thyroid gland Anatomy 0.000 claims 1
• 229960004605 timolol Drugs 0.000 claims 1
• 239000004408 titanium dioxide Substances 0.000 claims 1
• 230000001256 tonic effect Effects 0.000 claims 1
• 230000000699 topical effect Effects 0.000 claims 1
• 238000007070 tosylation reaction Methods 0.000 claims 1
• 238000013518 transcription Methods 0.000 claims 1
• 230000035897 transcription Effects 0.000 claims 1
• 230000009466 transformation Effects 0.000 claims 1
• 230000005945 translocation Effects 0.000 claims 1
• 230000017105 transposition Effects 0.000 claims 1
• 230000008733 trauma Effects 0.000 claims 1
• 229950005135 traxoprodil Drugs 0.000 claims 1
• 238000011277 treatment modality Methods 0.000 claims 1
• 150000003626 triacylglycerols Chemical class 0.000 claims 1
• 150000003918 triazines Chemical class 0.000 claims 1
• QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims 1
• CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 claims 1
• 229940029284 trichlorofluoromethane Drugs 0.000 claims 1
• ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 claims 1
• BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 claims 1
• RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims 1
• 238000001665 trituration Methods 0.000 claims 1
• 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
• GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 claims 1
• 229960001641 troglitazone Drugs 0.000 claims 1
• GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 claims 1
• 229960000281 trometamol Drugs 0.000 claims 1
• 210000002700 urine Anatomy 0.000 claims 1
• 229960004699 valsartan Drugs 0.000 claims 1
• SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 claims 1
• 229910052720 vanadium Inorganic materials 0.000 claims 1
• 239000002966 varnish Substances 0.000 claims 1
• 230000004218 vascular function Effects 0.000 claims 1
• 210000005166 vasculature Anatomy 0.000 claims 1
• 210000003462 vein Anatomy 0.000 claims 1
• 201000005539 vernal conjunctivitis Diseases 0.000 claims 1
• 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims 1
• 235000019163 vitamin B12 Nutrition 0.000 claims 1
• 239000011715 vitamin B12 Substances 0.000 claims 1
• 235000019165 vitamin E Nutrition 0.000 claims 1
• 239000011709 vitamin E Substances 0.000 claims 1
• 229940011671 vitamin b6 Drugs 0.000 claims 1
• 150000003722 vitamin derivatives Chemical class 0.000 claims 1
• 235000012431 wafers Nutrition 0.000 claims 1
• 229920003176 water-insoluble polymer Polymers 0.000 claims 1
• 229920003169 water-soluble polymer Polymers 0.000 claims 1
• 230000003442 weekly effect Effects 0.000 claims 1
• 239000000080 wetting agent Substances 0.000 claims 1
• 229940100445 wheat starch Drugs 0.000 claims 1
• 229910052725 zinc Inorganic materials 0.000 claims 1
• 239000011701 zinc Substances 0.000 claims 1
• OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 claims 1